a PDF version of the Final Program Book here

Transcription

45TH ANNUAL
ESDR MEETING
9-12 September 2015
Rotterdam, The Netherlands
PROGRAM BOOK
www.esdr2015.org
1
46TH ANNUAL
ESDR MEETING
7-10 September 2016
Munich, Germany
E
T
A
D
E
H
T
E
SAV
www.esdr2016.org
TABLE OF CONTENTS
Sponsors of the 45th Annual ESDR Meeting 2015
Meeting Organisers
Welcome to Rotterdam
Complete Daily Program Overview
Plan of Exhibition Area and Meeting Venue
Social Program SCIENTIFIC PROGRAM BELOW: See pp 6-7 for full program including breaks, ceremonies etc
Wednesday 9 September 2015
Dermatoendocrinology
2015 Future Leaders Symposium
European Epidermal Barrier Research Network (contains Thursday program also)
European Association of Dermato-Oncology Symposium
The Epidemiology of Psoriasis: Towards a Global Psoriasis Atlas
4
4
5
6
8
10
12
13
14
15
16
Thursday 10 September 2015
European Dermatoepidemiology Network
Neurobiology of the Skin
Eastern European Research
Drug Discovery and Translational Medicine
Frontiers in Skin Biology & Dermatology: Immunology
The LEO Pharma Research Foundation Awards 2015
First Steps Towards Personalized Medicine in the Treatment of Psoriasis
Plenary 1
Come See My Poster 1
2015 Celgene ESDR Guest Lecture: Kathleen J Green
Concurrent 1: Inflammation & Immunity 1
Concurrent 2: Hair, Cutaneous Homeostasis & Stem Cells
Concurrent 3: Photobiology & Pigmentation
Friday 11 September 2015
Intravenous Immunoglobulins in Dermatological Autoimmune Diseases
Cytokine Signalling in Psoriasis: Extracellular and Intracellular Therapeutic Targets
Recent Advances in Acne & Rosacea Research
2015 ESDR Guest Lecture: Cédric Blanpain
Plenary 2
Understanding Lupus: The Importance of the Ubiquitination Pathway
Rare Disease: Phenotypes and Genotypes
2015 René Touraine Guest Lecture: Marcus Maurer
Concurrent 4: Inflammation & Immunity 2: Psoriasis
Concurrent 5: Cell Adhesion and Repair
Concurrent 6: Cancer
2015 Rudi Cormane Lecture: Alexander Enk
32
33
34
35
36
37
38
39
40
41
42
43
44
Saturday 12 September 2015
Mitochondria and Skin Diseases
Consistency of Biologic Therapies: How Different is Similar?
Mechanisms of Neuroinflammation and Pruritus
Frontiers in Skin Biology and Dermatology: Omics
2015 EADV Guest Lecture: Susana Puig
Horizon 2020: EU Funding Opportunities
Clinical Saturday Lectures
Concurrent 7: Inflammation & Immunity 3: Disease Immunology
Concurrent 8: Clinical Research
Concurrent 9: Genetic Disorders and Disease Mechanisms
Concurrent 10: Epidermal Structure & Function
46
47
48
49
50
51
52
53
54
55
56
General Information
ESDR 2015 Meeting Venue, Transport Information, Opening Times, Exhibition Information
General and Practical Information
Poster Information (setup, electronic posters, prizes, poster walks)
58
59
60
18
19
20
21
22
23
24
25
26
27
28
29
30
SPONSORS OF THE 45th ANNUAL ESDR MEETING 2015
CORPORATE PARTNER
PLATINUM SPONSOR
PLATINUM SPONSORS
GOLD SPONSORS
Sponsors
Organisation
Local Organising Committee
Scientific Program Committee
European Society for Dermatological Research
Maarten Vermeer, Leiden (Chair)
Peter Steijlen, Maastricht (Co-Chair)
Mauro Picardo (Chair)
David Kelsell (Vice-Chair)
Salvador Aznar-Benitah
Jonathan Barker
Michel Gilliet
Mauro Picardo
Matthias Schmuth
Maarten Vermeer
Thomas Werfel
Thomas Florestan
Administrative-Director
Joke Bouwstra, Leiden
Carla Bruijnzeel, Utrecht
Rick Hoekzema, Amsterdam
Marcel Jonkman, Groningen
Peter van de Kerkhof, Nijmegen
Tamar Nijsten, Rotterdam
Marjon Pasmooij, Groningen
Errol Prens, Rotterdam
Menno de Rie, Amsterdam
Joost Schalkwijk, Nijmegen
Rein Willemze, Leiden
4
Professional Congress Organiser
Congress Bureau
Erasmus MC
Postbus 2040, 3000 CA Rotterdam
T: +31 10 704 38 81
F: +31 10 704 47 37
E: m.bot@erasmusmc.nl
W: http://www.erasmusmc.nl/congresbureau/
Caroline Blondel Baldassarre
Sponsorship & Membership Co-Ordinator
ESDR
7 Rue Cingra
CH-1205 Geneva
Switzerland
Tel: +41 22 321 48 90
Fax: +41 22 321 48 92
Email: office@esdr.org
http://www.esdr.org
Welcome to ESDR 2015
It is a great pleasure and a privilege to welcome you to the 45th
Annual Meeting of the European Society for Dermatological
Research.
The city of Rotterdam is Europe’s largest port city. It is a buzzing
metropolis with a constantly growing skyline full of modern
architecture and a city where more than 170 nationalities live
and work together. Rotterdam is well connected to international
travel hubs and offers a great range of hotel accommodations as
well as a stimulating international atmosphere.
The venue of the meeting, the Postillion Convention Centre-WTC,
is the beating heart of the international business community
in the Rotterdam region and is situated in the center of the city
with leisure opportunities and cultural activities within walking
distance.
The ESDR - together with the local organizing committee has assembled an exciting scientific program that will cover
the latest developments in cutaneous biology, clinical and
experimental dermatology. We trust that the ESDR Rotterdam
meeting will provide an opportunity to get inspiration from the
newest scientific information in cutaneous research, exchange
ideas, start new collaborations and make new friends.
We are looking forward to welcome you in person in Rotterdam to
what promises to be another excellent ESDR!
Maarten Vermeer
Chair, Local Organising Committee
Welcome from the ESDR President
On behalf of the ESDR Board I would like to welcome you to the
45th Annual Meeting of the European Society for Dermatological
Research in Rotterdam from 9-12 September 2015.
We have chosen a convenient location: easy to reach, easy to stay
in and hopefully easy to enjoy. The local organizing committee,
scientific program committee and the ESDR office have designed
a program that combines high quality research with the unique
opportunity to make new connections while expanding your
scientific knowledge.
The ESDR aims to organize scientific meetings facilitating
exchange between clinicians and scientists, a significant action
for the advancement of investigative dermatology.
The 2015 program includes invited lectures from outstanding
speakers, workshop symposia and educational events such as
Frontiers in Skin Biology and Dermatology, where emerging
scientists will contribute enthusiastically with their most recent
scientific advances.
ESDR dedicates much effort to mentoring young scientists and
clinicians via collegiality programs. Specific sections have been
introduced into the meeting plan such as the Future Leaders
Symposium. We disseminate topics in dermatological research
including some new technological approaches to scientific
programs. The Drug Discovery and Translational Research
session will bring together academic and industry partners
and encourage interactions and collaborations. The ESDR will
also host special interest groups and sister societies to provide
updates in different fields related to dermatology.
We have maintained the use of technologies to facilitate and
disseminate information, such as the meeting app and e-posters,
and aim to further improve the visibility and impact of posters
presented through the Come See My Poster and Poster Walk
sessions.
Based on last years’ meeting, around 1000 delegates from the
academic, clinical, and industrial areas are expected to attend
the meeting. We hope that while in Rotterdam you will interact
with international delegates and we invite you to discuss your
latest and hottest data in experimental and clinical research in
dermatology.
We look forward to a great meeting.
Mauro Picardo
President, European Society for Dermatological Research
5
Wednesday 9 September 2015
Program Overview
TIME
SESSION
LOCATION
INFORMATION
10.00-13.00
Oscar Auditorium
p 12
13.00-18.30
Diamond Room
p 13
13.00-17.50
European Epidermal Barrier Research Network (Part I)
Mees Room
p 14
13.30-16.30
European Association of Dermato-Oncology Symposium
Penn Room 1 & 2
p 15
14.00-17.30
Oscar Auditorium
p 16
Thursday 10 September 2015
Program Overview
6
TIME
SESSION
LOCATION
INFORMATION
08.00-10.30
European Dermatoepidemiology Network
Oscar Auditorium
p 18
08.00-10.30
Penn Room 1 & 2
p 19
08.30-10.30
Diamond Room
p 20
08.30-10.30
Rotterdam Hall
p 21
08.30-10.30
European Epidermal Barrier Research Network (Part 2)
Mees Room
p 14
10.30-11.00
COFFEE BREAK
11.00-11.15
Opening Ceremony
Rotterdam Hall
11.15-12.45
Rotterdam Hall
p 22
12.45-14.15
Rotterdam Hall
p 23
13.00-14.00
First Steps Towards Personalized Medicine in the Treatment of
Psoriasis
Diamond Room
p 24
14.15-15.45
Plenary 1
Rotterdam Hall
p 25
15.45-16.00
Rotterdam Hall
p 26
16.00-16.30
2015 Celgene ESDR Guest Lecture: Kathleen J. Green
Rotterdam Hall
p 27
16.30-17.00
COFFEE BREAK
17.00-18.30
Rotterdam Hall
p 28
17.00-18.30
Diamond Room
p 29
17.00-18.30
Oscar Auditorium
p 30
18.30-20.30
Welcome Reception & General Poster Viewing Session
Foyer/Poster Area
p 10
Friday 11 September 2015
Program Overview
TIME
SESSION
LOCATION
INFORMATION
08.30-09.30
Oscar Auditorium
p 32
08.30-09.30
Cytokine Signalling in Psoriasis: Extracellular and Intracellular Therapeutic
Targets
Rotterdam Hall
p 33
08.30-09.30
Diamond Room
p 34
09.30-10.00
2015 ESDR Guest Lecture: Cédric Blanpain
Rotterdam Hall
p 35
10.00-11.15
Plenary Session 2
Rotterdam Hall
p 36
11.15-11.30
Rotterdam Hall
p 37
11.30-13.00
COFFEE BREAK
Poster Viewing 1 (ODD NUMBERS), Poster Walks
p 60
13.00-14.30
Understanding Lupus: The Importance of the Ubiquitination Pathway
Rotterdam Hall
p 38
13.30-14.30
Diamond Room
p 39
14.30-15.00
2015 René Touraine Guest Lecture: Marcus Maurer
Rotterdam Hall
p 40
15.00-16.30
Rotterdam Hall
p 41
15.00-16.30
Diamond Room
p 42
15.00-16.30
Oscar Auditorium
p 43
16.30-17.00
COFFEE BREAK
17.00-17.15
Awards Ceremonies
2015 ILDS Certificate of Appreciation
SID/ESDR Intersociety Collegiality Awards
JSID/ESDR Intersociety Collegiality Awards
Rotterdam Hall
17.15-17.45
2015 Rudi Cormane Lecture: Alexander Enk
Rotterdam Hall
17.45-18.00
ESDR Honorary Membership Awards
p 44
18.00-19.00
ESDR Annual General Meeting of Members
Rotterdam Hall
19.30-24.00
Social Networking Event
Laurenskerk
p 10
Saturday 12 September 2015
Program Overview
TIME
SESSION
LOCATION
INFORMATION
08.30-09.30
Oscar Auditorium
p 46
08.30-09.30
Rotterdam Hall
p 47
08.30-09.30
Diamond Room
p 48
09.30-11.00
Rotterdam Hall
p 49
11.00-11.30
2015 EADV Guest Lecture: Susana Puig
Rotterdam Hall
p 50
11.30-13.00
COFFEE BREAK
Poster Viewing 2 (EVEN NUMBERS), Poster Walks
13.00-14.00
Diamond Room
p 51
13.30-14.30
Rotterdam Hall
p 52
13.30-14.30
Rotterdam Hall
p 53
14.30-16.00
Diamond Room
p 54
14.30-16.00
Oscar Auditorium
p 55
14.30-16.00
Concurrent 10: Epidermal Structure and Function
Mees Room
p 56
16.00-16.30
Closing Ceremony and Poster Prizes
Rotterdam Hall
p 60
7
Plan of Ground Floor: Exhibition and Poster Area
EXHIBITOR
IPC
Celgene
Aeon Astron Europe/Biomimiq
Cytoo
Fibrotx LLC
RiverD international
CELLnTEC Advanced Cell Systems
Booth Number
1
6
7
9
10
11
12
Plan of Main Meeting Rooms: Postillion Convention Centre-WTC
SOCIAL PROGRAM
THURSDAY 10 SEPTEMBER 2015, 18.30-20.30
ESDR 2015 Welcome Reception and Poster Viewing
Included in your registration fee
Our 2015 welcome reception will take place at the Postillion Convention Centre-WTC around the Poster Area. This is a
great opportunity to meet your colleagues and peers while discussing science. A light food and beverage buffet will be
served.
FRIDAY 11 SEPTEMBER 2015, 19.30-24.00
ESDR 2015 Social Networking Event
Tickets: Can be purchased when you register for the meeting or onsite at the meeting venue. Please purchase your
tickets early as places are limited.
Introduction
Join us for a fun and relaxing event on Friday night. This is the perfect occasion to meet with other delegates in an
informal environment. Food, beverage and music are included in the ticket price.
The event will be held at Laurenskerk (church of Saint Lawrence). The church was built between 1449 and 1525 and is
the only late-Gothic building to survive from medieval Rotterdam. Heavily damaged during the Second World War, the
church has since been renovated to its former state.
Laurenskerk
Grotekerkplein 27
3011 GC Rotterdam
Transport
As the Laurenskerk is located in the central city, a short walk from the meeting venue, no transport has been arranged.
Dress Code: Casual
10
WEDNESDAY
11
Date: Wednesday 9 September 2015
Time: 10.00-13.00
Room: Oscar Auditorium
Chairs: Ralf Paus (Manchester, UK & Münster, Germany) & Thomas Luger (Münster, Germany)
This satellite meeting is open to all registered ESDR delegates.
PROGRAM
insulin-induced sebogenesis and inflammation
Arianna Mastrofrancesco (Rome)
11.21-11.50
Coffee Break
11.50-12.15
Lecture 3: (17 min + 8 min discussion)
(Neuro-)endocrine control of energy metabolism
in human skin: From keratinocyte mitochondrial
biogenesis to skin aging
Ralf Paus (Manchester/Münster)
10.00-10.05
Welcome
Thomas Luger
10.05-10.30
PPAR, LXR, and PXR signaling in epidermal
homeostasis, inflammation, and xenobiotic responses
Matthias Schmuth (Innsbruck)
10.30-10.55
Perspectives for the use of a-MSH-derived peptides in
clinical dermatology
Thomas Luger (Münster)
12.15-12.27
Oral presentation of selected ESDR abstract C (7 min +
5 min discussion)
Mucosal type mast cell degranulation and proliferation
are stimulated by CRH in situ
Koji Sugawara (Osaka)
10.55-11.07
Oral presentation of selected ESDR poster abstract A
(7 min + 5 min discussion)
Beyond the adrenal gland: The essential role of skinsynthesised glucocorticoids in health and disease
Rosalind Hannen (London)
12.27-12.52
Lecture 4: (17 min + 7 discussion)
11.07-11.21
Oral presentation of selected ESDR poster abstract B
(7 min + 5 min discussion)
The role of sex steroids in skin aging and wound
healing
Matthew Hardman (Manchester)
The role of PPARγ modulation in the control of the
12.52-13.00
Closing remarks
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
12
What is the Future of Dermatological Research?
Time: 13.00-18.30
Location: Diamond Room
Program Organizing Committee
ESDR: David Hill, Ellen Van Den Bogaard, Matthew Caley JSID: Masatoshi Jinnin, Yoshihide Asano SID: Christian Posch, John O’Malley
Goal
To facilitate interaction and collaboration between young ambitious researchers and current leaders in the field of investigative dermatology
worldwide.
The 2015 Future Leaders Symposium is generously supported by:
PROGRAM
12.30-13.00
Registration
13.00-13.20
Welcome and introduction to Future Leaders Symposium
ESDR: David Hill
JSID: Masatoshi Jinnin
SID: Christian Posch
Session 1
Chairs: Christian Posch and Matthew Caley
13.20-13.50
Keynote Speaker 1
Your Barriers
Howard Maibach (UCSF School of Medicine, USA)
Scientific Presentations (15min + 3 min questions)
13.50-14.10
The Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways
Timo Buhl (University Medical Center Gottingen, Germany)
14.10-14.30
Mcl-1L Protects Melanocytes and Melanoma Cells from Ultraviolet B-induced Apoptosis via MEK-ERK-STAT3 Signaling Pathway:
A Mechanism Essential for Melanoma Development
Takeshi Fukumoto (Kobe University, Japan)
14.30-14.50
Stem Cell Therapies
Tobias Schatton (Brigham and Women’s Hospital, USA)
14.50-15.20
Special Guest Presentation
Nanotechnology in Heath Sciences
Dave Blank (University of Twente, The Netherlands)
15.20-15.50
Coffee Break
Session 2
Chairs: Ellen Van Den Bogaard and Yoshihide Asano
15.50-16.40
Interactive session with concurrent ‘laptop’ presentations on the theme of ‘future dermatology research’
1.
2.
3.
4.
5.
16.40-17.10
Keynote Speaker 2
How to Decide your Research Project
Kenji Kabashima (Kyoto University, Japan)
17.10-17.40
Keynote Speaker 3
How to Write a Research Grant and Secure Funding
Christina Zielinski (Technical University Munich, Germany)
17.40-17.45
Closing Remarks
17.45-18.30
Closing reception for symposium participants
18.45-
Future Leaders and Alumni Dinner (requires pre-registration)
High-throughput T cell receptor sequencing – John O’Malley (Brigham and Women’s Hospital, USA).
Skin microbiome – Tom Ederveen (Radboud University, Nijmegen, The Netherlands).
Stem cell therapies – Antoni Gostynski (University of Groningen, University Medical Center Groningen, The Netherlands).
The 3Rs in dermatology and 3D skin models – Sarah Zwart (Leiden University Medical Center, Leiden, The Netherlands).
Skin Inflammageing – Dr Suzanne Pilkington (Manchester University, UK).
13
13th Meeting of the European Epidermal Barrier Research Network (E²BRN)
Date: Wednesday 9 September 2015, Thursday 10 September 2015
Room: Mees Room
Scientific Organising Committee: Sandrine Dubrac (Innsbruck, Austria) and Patrick Zeeuwen (Nijmegen, The Netherlands)
PROGRAM
WEDNESDAY 9 SEPTEMBER 2015
Session 1: Skin Barrier: Mechanisms of Disease
Chairs: Johanna Brandner (Hamburg) & Patrick Zeeuwen (Nijmegen)
13.00-13.05
Opening
Johanna Brandner
13.05-13.30
Keynote Lecture 1 (20 min + 5 min discussion)
Barrier and Bases
Stephan Weidinger (Kiel, Germany)
13.30-13.55
Interaction of the Tight Junction Barrier and the
Stratum Corneum Barrier
Johanna Brandner (Hamburg, Germany)
13.55-14.40
3 Short communications chosen from the abstracts (12
min + 3 min discussion each)
13.55 – 14.10: Inflammation and Stress: The Epidermal
Tight Junctions under Attack
Laura Ivanovas (Gießen, Germany)
14.10 – 14.25: In silico Models to Study the Onset,
Progression and Prevention of AD
Elisa Domínguez-Hüttinger (London, UK)
14.25 – 14.40: Skin Penetration and Tumor Specific
Cellular Uptake of G5G2.5 tecto-dendrimer
Nanoparticles as a New Strategy for Targeted Delivery
by Topical Application
Alexander Boreham (Berlin, Germany)
14.40-16.00
Coffee break + poster session
Session 2: Organotypic 3D Cultures: Models to Study Atopic Dermatitis
Chairs: Sandrine Dubrac (Innsbruck) & Katja Bäsler (Hamburg)
16.00-16.25
Gene Editing of Human Pluripotent Stem Cells in
Modeling Atopic Dermatitis in vitro
Dusco Ilic (London, UK)
16.25-16.50
17.35-17.50
Poster Prizes THURSDAY 10 SEPTEMBER 2015
Session 3: Skin Barrier Homeostasis
Chairs: Michel Simon (Toulouse) & Stefan Blunder (Innsbruck)
08.30-08.55
BARRIERS: Lessons Learned
Howard Maibach (San Francisco, USA)
08.55-09.20
Epidermal Permeability Barrier: Lessons from
Monogenetic Disease
Matthias Schmuth (Innsbruck, Austria)
09.20-09.45
The Aryl Hydrocarbon Receptor (AHR) in Skin Barrier
Homeostasis and Disease
Ellen van den Bogaard (Nijmegen, The Netherlands)
Innervated Skin Models: Implication for Atopic
Dermatitis
Gitta Neufang (Hamburg, Germany)
09.45 – 10.00: TMEM45A Gene Expression is
Dispensable for Epidermal Keratinization and
Morphogenesis
Aurelie Hayez (Namur, Belgium)
16.50 – 17.05: Cholesterol-depletion Followed by
Interleukins-4, -13 and –25 Enhances Alterations in a
Reconstructed Human Epidermis
Evelyne De Vuyst (Namur, Belgium)
14
17.20 – 17.35: TAp63β and Notch in Human Skin
Differentiation
Li Fang Koh (Singapore)
09.45-10.30
16.50-17.35
17.05 – 17.20: Altered Epidermal Lipid Biosynthesis in
Patients with Atopic Dermatitis
Jeroen van Smeden (Leiden, The Netherlands)
10.00 – 10.15: p38 Map Kinase Compensates Barrier
Dysfunction Caused by Loss of Epidermal Insulin/IGF1 Signaling
Christian Günschmann (Cologne, Germany)
10.15 – 10.30: A Novel Nrf2-Il-36γ Pathway Mediates
Paracrine Growth Control of Keratinocytes
Matthias Schäfer (Zurich, Switzerland)
European Association of Dermato-Oncology Symposium (EADO)
Time: 13.30-16.30
Location: Penn Room 1 & 2
Chairs: Céleste Lebbe, Veronique del Marmol, Jean Jacques Grob
This session is open to all registered ESDR meeting delegates.
PROGRAM
13.30-13.40
Introduction
Céleste Lebbe
13.40-14.00
Neo Antigens and Immunotherapy of Cancer
John Haanen (The Netherlands)
14.00-14.20
Improving Melanoma Patient Outcome with Autologous Dendritic Cell Therapy
Bart Neyns (Belgium)
14.20-14.40
How Adjuvant Therapy could Push the Limits of Early Detection
Jean Jacques Grob (France)
14.40-15.00
Genetics in Melanoma: New Targets
Nicolas Dumaz (France)
15.00-15.20
Telomere length is Important for Melanoma Susceptibility but may Affect Mortality
Veronique Bataille (UK)
15.20-15.40
Gene-Environment Interactions in Melanoma
Amaya Viros (UK)
15.40-16.00
Melanoma Epidemiology: Burden of the Disease and Multiple Skin Cancer
Loes Hollenstein (Netherlands)
16.00-16.30
Discussion and Concluding Remarks
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
15
Time: 14.00-17.30
Overview
A project under the auspices of the International League of Dermatological Societies (ILDS), the International Federation of Psoriasis
Associations (IFPA) and the International Psoriasis Council (IPC), the Global Psoriasis Atlas will be the leading epidemiological web-based
resource on psoriasis globally informing research, policy and health care provision of the disease worldwide. This workshop will outline
the need for this project and provide participants the opportunity to discuss processes that will determine the worldwide epidemiology of
psoriasis.
Format: Faculty panel; Q & A after each topic and end of program
Program chair: Prof Christopher Griffiths (Manchester)
Faculty
Prof Darren Ashcroft (Manchester, United Kingdom)
Prof Matthias Augustin (Hamburg, Germany)
Prof Luigi Naldi (Bergamo, Italy)
Prof Tamar Nijsten (Rotterdam, The Netherlands)
Dr Carsten Flohr (London, United Kingdom)
PROGRAM
14.00-14.10
Welcome and introductions
Chris Griffiths
14.10-14.35
Temporal trends in the epidemiology of psoriasis in the United Kingdom: population-based study using the Clinical Practice
Research Datalink
Darren Ashcroft
14.35-15.00
Use of multi-source data to determine psoriasis epidemiology
Matthias Augustin
15.00-15.25
Lessons from studies on the epidemiology of Atopic Dermatitis
Carsten Flohr
15.25-15.45
Break
15.45-16.05
The clinical epidemiology of psoriasis: an insight through registry data
Luigi Naldi
16.05-16.30
Psoriasis & cardiovascular comorbidities: unravelling the maze
Tamar Nijsten
16.30-16.55
A Global Psoriasis Atlas
Chris Griffiths
16.55-17.15
Audience Q & A
17.15-17.30
Conclusion and adjournment
Chris Griffiths
16
THURSDAY
17
European Dermatoepidemiology Network (EDEN)
Date: Thursday 10 September 2015
Time: 08.00-10.30
Chairs: Tamar Nijsten, Sinéad Langan
This session is open to all registered ESDR delegates.
PROGRAM
08.00-08.05
Welcome
08.06-08.16
Celebrating 20 years of EDEN
08.16-08.47
Personalised Medicine for Skin Diseases
Nick Reynolds (Newcastle-upon-Tyne)
08.48-09.03
Interventions for Nail Psoriasis
Celine Busard (Amsterdam)
09.04-09.19
Cessation of Spread as a Motivation for Treatment in Vitiligo
Reinhart Speeckaert (Gent)
09.20-09.35
Examining the Prevalence of Alcohol Use Disorders (AUD) in Patients with Skin Disease, A Cross-Sectional Study
Khadija Aljefri (Newcastle-upon-Tyne)
09.36-09.51
Ordinal Regression in the Mapping of DLQI Scores to EQ-5D Utility Values: Is it Plausible?
Faraz Ali (Cardiff)
09.52-10.23
Population Genomics: Life after GWAS
André Uitterlinden (Rotterdam)
10.24-10.30
Closing Remarks
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
18
Time: 08.00-10.30
Room: Penn Room 1 & 2
Chairs: Anna Zalewska (Lodz, Poland) & Marcus Maurer (Berlin, Germany)
This session is open to all registered ESDR delegates.
PROGRAM
08.00-08.05
Welcome and Introduction
Anna Zalewska (Lodz, Poland)
08.05-08.25 Molecular Mechanisms of Pruritus
Martin Steinhoff (Dubin, Ireland)
08.25-08.45
Sensory Processing of Chronic Pruritus: Investigations in the Cowhage Model
Manuel P. Pereira (Münster, Germany)
08.45-09.05
Frontiers in Cutaneous Neuroendocrinology: Recent Pointers from Endocannabinoid, Prolactin and Trh Research
Ralf Paus (Manchester, UK)
09.05-09.25
Sensitive Skin
Laurent Misery (Brest, France)
09.25-09.45
Atopic Dermatitis and Stress
Klas Nordlind (Stockholm, Sweden)
09.45-10.05
Placebo Effects and their Psychoneurobiological Underpinings in Dermatological Condtions
Andrea W.M. Evers (Leiden, The Netherlands)
10.05-10.25
Neurodermatology on the Move
Anna Zalewkska (Lodz, Poland)
10.25-10.30
Closing Remarks
Marcus Maurer (Berlin, Germany)
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
19
Time: 08.30-10.30
Room: Diamond Room
Chair: Zsuzsanna Bata-Csörgo (Szeged), Johann Bauer (Salzburg)
PROGRAM
08.30-08.40
MicroRNA-146a Alleviates Chronic Skin Inflammation in Atopic Dermatitis through Suppression of Innate Immune Responses in
Keratinocytes
Ana Rebane (Tartu)
08.40-08.50
Cannabidiol Exerts Sebostatic and Antiinflammatory Effects on Human Sebocytes
Attila Oláh (Debrecen)
08.50-09.00
Regulatory T-cell Subsets with Aquired Functional Impairment: Important Indicators of Disease Severity in Atopic Dermatitis
Krisztián Gáspár (Debrecen)
09.00-09.10
Dermoscopic Features in Different Morphologic Types of Basal Cell Carcinoma
Mirjana Popadic (Belgrade)
09.10-09.40
Keynote Speaker
Immunological Dysfunctions and Barrier Alterations in Atopic Dermatitis
Andrea Szegedi (Debrecen)
09.40-09.50
CARD14 Frameshift Mutation via CRISPR/Cas Genome Editing Leads to IL8 Inhibition
Alena Zolotarenko (Moscow)
09.50-10.00
Transient Receptor Potential Vanilloid-4 Inhibits Human Hair Growth
Imre Szabó (Debrecen)
10.00-10.10
Human Constitutive Photomorphogenic Protein Down-Regulation Modulates Cancer-Relevant Gene Expression in Keratinocytes
and Sensitizes the Cells to Cisplatin
Barbara Fazekas (Szeged)
10.10-10.20
Vitamin D Analogues Selectively Modulate the Expression of Neuropeptides in Skin
Justyna M. Wierzbicka (Gdansk)
10.20-10.30
2015 EER Awards
About the EER Awards
The European Society of Dermatological Research and the Austrian Society of Dermatology are jointly engaged in fostering dermatological research
in Eastern Europe. Together they sponsor awards to provide recognition to young and established academic dermatologists in this area.
The 2015 “Academic Leader” award will be presented to Andrea Szegedi (Debrecen).
The 2015 “Research Fellow” awards will be presented to Attila Oláh (Debrecen), Krisztián Gáspár (Debrecen), Mirjana Popadic (Belgrade), Ana
Rebane (Tartu)
20
Time: 08.30-10.30
Room: Rotterdam Hall
Chairs: Chris Griffiths, Mauro Picardo
PROGRAM
08.30-08.35
Introduction
Chris Griffiths (Manchester, United Kingdom)
08.35-09.00
Protection of Human Skin against Environmental Novae - From Mechanistic Studies to Novel Products
Jean Krutmann (Düsseldorf, Germany)
09.00-09.25
University: Industry partnerships in the Development of Effective Anti-ageing Solutions
Mike Bell (Boots, United Kingdom)
09.25-09.50
Working at the Academic: Industry interface. Towards a Better Understanding of Skin Rejuvenation
Rachel Watson (Manchester, United Kingdom)
09.50-10.15
Successful Public/Private Partnerships to Develop Innovative Products
Hélène Duplan and Jean-Jacques Voisard (Pierre-Fabre, France)
10.15-10.30
Interactive Discussion
FACULTY
Jean Krutmann
Jean Krutmann is Professor of Dermatology and Environmental Medicine and Director of the IUF – Leibniz Institut for Environmental
Medicine at the Heinrich-Heine-University Düsseldorf. His research is in the field of dermatotoxicology and immunodermatology
with special emphasis on environmentally-induced skin diseases. He is author or co-author of more than 400 publications. He is the
recipient of the International Arnold-Rikli-Award, the Albert Fleckenstein Award, the Paul Gerson Unna Award, the Oscar Gans Award,
the C.E.R.I.E.S.Research Support Award and the Dermopharmacy Innovation Award. He is member of the editorial board of severals
journals: Skin Pharmacology and Applied Skin Physiology (since 1992), Photodermatology, Photoimmunology, Photomedicine
(since 2004), Environmental Medicine (since 2005), Experimental Dermatology (since 2010). He is Associate Editor of Der Hautarzt
(The Dermatologist) (since 2001) and the Journal of Dermatological Sciences (since 2008). He is visiting and adjunct professor of
dermatology at the Nagoya City University, Japan, Case Western Case Western Reserve University, Cleveland, Ohio and University of
Alabama, Birmingham, AL, USA and recipient of an international visiting professor fellowship of the Chinese Academy of Sciences
(CAS). He is a member of the National Academy of Sciences of Germany and Xu Guang Qi Lecturer, Shanghai Institute for Biological
Sciences (CAS), Shanghai, China.
Mike Bell
Dr Mike Bell, Skincare Scientific Advisor for Walgreens Boots Alliance, holds a BSc in Pharmacology (Hons 1st Class) and a Doctorate
(DPhil) in Neurobiology from Oxford University. His interests in skin science began in 1995 when he joined Procter & Gamble as a
formulation scientist, working on projects including Olay’s Total Effects. In 2003 he took a break to teach science to secondary school
children before returning to the cosmetics industry in 2007 with Boots UK in Nottingham and contributing to the success of the original
No7 Protect & Perfect Serum and No7 Protect & Perfect Intense Serum which established No7 as a leading skin care brand in the UK.
Mike became Skincare Scientific Advisor for Boots UK in 2010, responsible for leading the skin research programmes with universities
and dermatologists and the scientific support behind No7’s products.
Rachel Watson
Dr Watson graduated from the University of Sheffield with a BSc (Hons) in Anatomy & Cell Biology in 1992. She continued on at
Sheffield under the supervision of Professor Carl Pearson for her PhD, which investigated the utility of the cell line NTera2 for
modelling neurodegenerative diseases. In 1994, she moved to the University of Manchester to take up a research position in the
Wellcome Trust Centre for Cell-Matrix Research; during this period, she completed the writing of her PhD. In 2001, Rachel moved into
the NHS as a Clinical Scientist, working alongside Prof Chris Griffiths at Salford Royal Foundation Trust. In 2009, she was appointed as
a Senior Lecturer at the University of Manchester, and was promoted to Reader in 2014. Rachel’s research focuses on understanding
human ageing, with particular reference to skin. The ageing process can be divided broadly into two categories: that which occurs as
a consequence of time (intrinsic ageing) and that which is the result of an individual’s interactions with their environment (extrinsic
ageing). The major environmental factor which impacts upon skin is long-term sun exposure (ultraviolet radiation, UVR), although
other stimuli also exert effects (sun-bed use, smoking, atmospheric pollutants etc). In addition to examining the mechanisms
underlying skin ageing, Rachel also has an interest in understanding remodelling and repair of human skin occurs once damaged.
This translational includes understanding how drugs, such as retinoids, interact with the skin to promote repair, dietary protection
against UVR-mediated damage and performing ‘proof of principle’ in vivo clinical studies on emerging therapies. She is supported by
a wide range of funders including the MRC, BBSRC, Wellcome Trust and commercial companies.
21
Time: 11.15-12.45
Chairs: Nick Reynolds, Thomas Werfel
Introduction
Dermatology has numerous interfaces with basic science fields. Thus, a constant update in these areas is crucial for the further development
of dermatological research. The purpose of the Frontiers in Skin Biology and Dermatology lectures is to provide overviews about about
emerging fields in science including non-dermatological topics that are relevant for experimental and clinical dermatology. These talks are
principally intended as essential updates for “non-experts”. The Frontiers lectures are likely to be two of the most popular sessions at the
2015 ESDR meeting.
PROGRAM
11.15-11.45
Regulatory T cells in Skin Inflammation
Iris Gratz (Salburg)
11.45-12.15
Revealing the Dynamics of T cell Differentiation: An Integrated Approach of Genomics, Modelling and Molecular Immunology
Masahiro Ono (London)
12.15-12.45
The Impact of Type 2 Immunity on Epithelial Dysregulation and Carcinogenesis in the Skin
Jessica Strid (London)
FACULTY
Iris Gratz
Iris Gratz received her PhD in Immunology from the University of Salzburg, Austria. She then trained as a postdoctoral fellow with Prof
Johann Bauer at the EB House Austria at the University Hospital Salzburg, where she started her research on immune regulation of
the skin. At the University of California, San Francisco (UCSF), she further trained with Prof Abul Abbas, an internationally renowned
expert in immune tolerance and autoimmunity. In 2012, Iris Gratz, became Junior Faculty at UCSF and in 2014 she joined the junior
faculty of the University of Salzburg. The principal goal of her research is to investigate the mechanisms of immune regulation in
peripheral tissues. Her group is specifically interested in the biology of tissue resident regulatory T cells and their role in inflammatory
settings, such as skin autoimmunity and skin gene therapy (of patients with Epidermolysis bullosa). Iris Gratz’s group develops and
employs novel mouse models, including humanized mouse models, to elucidate the role of regulatory T cells in tissues, define the
requirements for their generation, recruitment and maintenance in the target tissue. The long-term goal is to develop approaches to
manipulate antigen-specific immune responses therapeutically.
Masahiro Ono
Dr Masahiro Ono was originally trained as a dermatologist, and later specialised in molecular and systems immunology. He obtained
his PhD in 2006 on autoimmunity and regulatory T cells, and thereafter, worked on the molecular mechanism of the transcription
factor Foxp3, revealing the interaction of Foxp3 and the transcription factor Runx1 and their transcriptional mechanisms. In 2009,
Dr Ono obtained a Human Frontier Science Program Long-Term Fellowship, and thereby joined University College London (UCL).
Thus he extended his expertise to genomics and systems analysis, establishing a new multidimensional framework for visualising
transcriptomic data and unravelling complex processes in T cell differentiation. Dr Ono was awarded a prestigious Biotechnology
and Biological Sciences Research Council (BBSRC) David Phillips Fellowship, thereby became a PI at UCL in 2013, and has been
conducting multidisciplinary projects on the transcriptional programme of T cell memory and immune regulation. His approach
integrates in vivo and molecular immunology, multidimensional genomics, and mathematical/ computational modelling.
Jessica Strid
Dr Strid did her MSc degree at the Danish University of Pharmaceutical Sciences in Copenhagen. She did her PhD in immunology
at the Institute of Child Health, University College London, UK under supervision of Stephan Strobel and Robin Callard. Her PhD
was focused on food allergy and skin immunology. During her PhD she discovered that the skin microenvironment is particularly
well suited for the induction of type 2 immunity and that primary allergic sensitization with high levels of IgE can occur via the skin.
As a PostDoc she joined Adrian Hayday’s research group at Kings College London and later worked at Cancer Research UK. Her
PostDoc studies were focused on autologous ‘sterile’ stress responses in the skin, their recognition by resident immune cells and
consequences for local and systemic immunity. These studies revealed that immune surveillance of stressed epithelia is linked to
atopic responses. In July 2012 Dr Strid joined Imperial College London as a non-clinical lecturer and the following year was awarded
the Wellcome Trust New Investigator Award. Her current work focuses on skin immune surveillance and the role of type 2 immunity
in tissue homeostasis and carcinogenesis.
22
Time: 12.45-14.15
Introduction
Each year, the LEO Pharma Research Foundation awards two scientists from the global science community with the aim of supporting
significant advances in scientific research. In collaboration with European Society for Dermatological Research, LEO Pharma Research
Foundation will present this year’s Gold and Silver award winners at the annual awards ceremony. The ceremony will feature scientific talks
by the award winners and a keynote lecture by Matthias Schmuth, Professor and Chair, Dept of Dermatology, Medical University of Innsbruck,
Austria.
This symposium is open to all registered ESDR delegates. Lunch boxes will be provided.
PROGRAM
12.45-12.50
Introduction to the Awards Ceremony
Dr Tord Labuda (The LEO Pharma Research Foundation)
12.50-13.00
Introduction to the Award Winners and Presentation of the Awards
Prof Mauro Picardo (ESDR President, Rome)
13.00-13.25
Gold Award Winner Lecture
Metagenomics of the Skin: Results and Perspectives on our Microbial Interface
Dr Nicola Segata (Trento)
13.25-13.50
Silver Award Winner Lecture
Specific Immunity in Chronic Inflammatory Skin Diseases
Prof Kilian Eyerich (Munich)
13.50-14.15
Keynote Lecture
Nuclear Receptor-Inflammation Crosstalk: Bench to Bedside
Prof Matthias Schmuth (Innsbruck)
This symposium is supported by LEO Pharma Research Foundation.
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
23
First Steps Towards Personalized Medicine in the Treatment of Psoriasis
Time: 13.00-14.00
Room: Diamond Room
Chair: Errol Prens (Erasmus MC, Rotterdam)
This symposium is open to all registered ESDR delegates.
PROGRAM
13.00-13.05
Welcome and Introduction
Errol Prens (Rotterdam)
13.05-13.25
Therapeutic Drug Monitoring
Martijn van Doorn (Rotterdam)
13.25-13.45
Biomarkers as Predictors of Therapeutic Response
Antonio Costanzo (Rome)
13.45-14.00
Plenary Panel Discussion
This educational symposium is supported by Janssen.
NOTES
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
24
Plenary Session 1
Time: 14.15-15.45
Chairs: Richard Gallo, Mauro Picardo, Shinichi Sato
The duration of each plenary talk is 8 minutes plus 2 minutes discussion. At the conclusion of this session, there will be a 15-minute “Come See My
Poster Session”
14.15-14.25
ORAL 001 [POSTER 315]
Mutations in SERPINB8 underlie a mild peeling skin phenotype
M Pigors,1 L Heinz,2 V Plagnol,3 J Fischer,2 M Kharfi,4 GG Lestringant,5 D Kelsell1 and DC Blaydon1 1Blizard Institute, Centre for
Cutaneous Research, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United
Kingdom, 2Institute of Human Genetics, University Medical Center Freiburg, Germany, 3Genetics Institute, University College
London, United Kingdom, 4Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia and 5British Ministry of Defence,
London, United Kingdom
14.25-14.35
Klk5 knock-out reverses cutaneous hallmarks of Netherton syndrome
L Furio,1 G Pampalakis,2 I Michael,3 A Nagy,3 G Sotiropoulou2 and A Hovnanian1 1INSERM UMR 1163, Laboratory of Genetic Skin
Diseases, Imagine Institute, University Paris Descartes - Sorbonne Paris Cité, Paris, France, 2Department of Pharmacy, School of
Health Sciences, University of Patras, Rion-Patras, Greece and 3Samuel Lunenfeld Research Institute, MountSinai Hospital, Toronto,
ON, Canada
14.35-14.45
Individual naïve T cells give rise to both TRM and TCM after 3 different skin immunizations
O Gaide,1 RO Emerson,2 X Jiang,3 H Robins,2 R Clark3 and TS Kupper3 1Dermatology, CHUV, Lausanne, Switzerland, 2Adaptive
Biotech, Seattle, USA and 3Dermatology, Brigham and Women’s Hospital, Boston, USA
14.45-14.55
Humanized mice overexpressing the pregnane x receptor in the epidermis exhibit a skin barrier defect associated with a Th2/
Th17 immune response resembling non lesional AD
A Elentner,1 N Yannoutsos,2 S Blunder,1 R Gruber,1 V Moosbrugger-Martinz,1 M Schmuth1 and S Dubrac1 1Department of
Dermatology and Venereology, Medical University of Innsbruck, Innsbruck, Austria and 2Gene Regulation and Immunology
Laboratory, Department of Cell Biology, Medical University of Innsbruck, Innsbruck, Austria
14.55-15.05
MicroRNA-132 supports wound healing by enhancing inflammatory-proliferative phase transition
D Li,1 A Wang,2 F Meisgen,1 J Grünler,1 S Catrina,1 M Ståhle1 and NX Landén1 1Karolinska Institutet, Stockholm, Sweden and 2The
Second Affiliated Hospital of Dalian Medical University, Dalian, China
15.05-15.15
Newly defined ABCB5-expressing dermis mesenchymal stem cells promote healing of chronic wounds via secretion of
interleukin-1 receptor antagonist
S Vander Beken,1 A Sindrilaru,1 JC de Vries,1 A Kluth,2 B Over,2 C Ganss,2 NY Frank3 MH Frank,3 M Wlaschek1 and K ScharffetterKochanek1 1Dermatology and Allergic Diseases, Ulm University, Ulm, Germany, 2Ticeba GmbH, Heidelberg, Germany and 3Medicine,
Brigham and Women’s Hospital, Boston, USA
15.15-15.25
Nrf2 activation promotes cutaneous wound healing by keratinocyte protection and stem cell activation
SS Muzumdar, H Hiebert, S Werner and M Schäfer Institute of Molecular Health Sciences, ETH Zürich, Zürich, Switzerland
15.25-15.35
Interfering with stem cell-specific gatekeeper mechanisms and p53 activity results in mutant Lef1-driven skin tumour formation
K Reuter and C Niemann Center for Biochemistry II and Center for Molecular Medicine Cologne, University of Cologne, Germany
25
Time: 15.45-16.00
Chairs: Richard Gallo, Mauro Picardo, Shinichi Sato
Introduction
The Come See My Poster sessions take place at directly after Plenary 1 and Plenary 2. These sessions give an opportunity for presenting
selected authors of highly ranked posters to give a brief one-minute introduction to their work displayed at the meeting.
Poster
021
Autoantibodies to parts of type XVII collagen outside of the non-collageneous 16A domain lead to mild bullous pemphigoid due to
the non-depletion of autoantigen
H Iwata,1 K Imafuku,1 K Izumi,1 M Wada,2 K Natsuga,1 H Ujiie,1 W Nishie1 and H Shimizu1 1Dermatology, Hokkaido University Graduate
School of Medicine, Sapporo, Japan 2Oral Diagnosis & Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
111
Mast cell-derived vascular endothelial growth factor contributes to tumor growth
A Rabenhorst,1 S Leja,1 A Florin,2 A Förster,1 LC Heukamp,2 RT Ullrich,3 S Willenborg,1 S Eming,1 R Büttner2 and K Hartmann1
1
Department of Dermatology, University of Cologne, Germany, 2Institute of Pathology, University of Cologne, Germany and 3Clinic I of
Internal Medicine, University of Cologne, Germany
112
Virus -host interactome of oncoproteins and capsid proteins of Merkel cell polyomavirus
A Touze,1 N Jerome,1 M Samimi,1 Y Jacob,2 C Demeret2 and M Ferté Chaudoy1 1University of Tours, Tours, France and 2Institut
Pasteur, Paris, France
113
Anti-tumor effect of an epithelial microRNA, miR-203, in melanoma
W Lohcharoenkal, L Zhang, NX Landén, M Ståhle, L Girnita, E Sonkoly and A Pivarcsi Karolinska Institutet, Stockholm, Sweden
165
Collagen XII variants in skin repair and fibrosis
K Schoenborn,1 J Schulz,1 M Koch,2 T Krieg1 and B Eckes1 1Department of Dermatology, University of Cologne, Germany and
2
Experimental Dentistry & Oral Musculoskeletal Biology, University of Cologne, Germany
167
Fibroblasts from the elderly produce in vitro fibroplasia slowly, a phenomenon that is enhanced by a fibronectin peptide
F Lin,2 M Tonnesen1 and RA Clark2 1Medicine, VA Medical Center, Northport, USA 2Dermatol & Biomed Eng, SBU, Stony Brook, USA
188
Gross cystic disease fluid protein 15 as a potential marker for decreased sweating in atopic dermatitis
K Kamiya, J Sakabe, H Yamaguchi, T Suzuki, T Yatagai, M Aoshima, T Ito and Y Tokura Department of Dermatology, Hamamatsu
University School of Medicine, Hamamatsu city, Japan
189
Elongated microparticle penetration profiling reveals potential for enhanced transepidermal drug delivery in distict body sites
despite differences in strata composition
T Prow, T Liu, H Soyer and M Ardigo Dermaology Research Centre, University of Queensland, Brisbane, QLD, Australia
196
26
Prevalence of musculoskeletal complaints and psoriatic arthritis in primary care patients with psoriasis
MC Karreman,1 A Weel,2 M van der Ven,1 M Vis,1 I Tchetverikov,3 T Nijsten,4 M Wakkee,4 J Hazes1 and J Luime1 1Rheumatology,
Erasmus University Hospital, Rotterdam, Netherlands, 2Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology,
Albert Schweitzer Hospital, Dordrecht, Netherlands and 4Dermatology, Erasmus University Hospital, Rotterdam, Netherlands
2015 Celgene ESDR Guest Lecture
Desmosomes: Structural and Signaling Scaffolds of Surprising Diversity
Time: 16.00-16.30
Introduced by: David Kelsell
Kathleen J. Green, PhD
Joseph L. Mayberry Professor
Depts of Pathology and Dermatology
Northwestern University Feinberg School of
Medicine
Chicago, USA
Kathleen Green is the Joseph L. Mayberry Professor of Pathology
at Northwestern University and Professor in the Department of
Dermatology. She serves as Associate Director for Basic Sciences in the
R.H. Lurie Comprehensive Cancer Center.
Kathleen Green’s pioneering studies demonstrate how intercellular
adhesive junctions called desmosomes contribute to the development
and maintenance of multicellular tissues. Their essential nature is
underscored by the existence of genetic, autoimmune and bacterial toxin-
mediate diseases caused by interference with desmosome function. Her
work led to the discovery of a protein family, now known as “plakins”
and facilitated the identification of desmoplakin mutations resulting in
disorders called “Desmoplakinopathies.” Dr. Green’s work helped shift
the view of desmosomes as mere spot welds to one in which these
structures function as spatiotemporal signal integrators to coordinate
adhesion, cell shape and differentiation status.
Kathleen Green is a Fellow of the American Association for the
Advancement of Science, a Keith Porter Fellow, and recipient of a
MERIT Award from the National Institutes of Health. She received the
Distinguished Women in Medicine and Science Award from Northwestern
University in 2011 and the Martin and Gertrude Walder Award for
Research Excellence in 2012. A previous William Montagna and Tanioku
Kihei lecturer, Dr. Green was President of the Society for Investigative
Dermatology from 2010-11 and is currently Secretary of the American
Society for Cell Biology. Kathleen Green serves as Associate Editor for
the Journal of Investigative Dermatology and Deputy Editor in Chief of the
Journal of Cell Science.
Selected Publications
Simpson, C.L., D. Patel and K.J. Green. (2011). Deconstructing the skin: cytoarchitectural determinants of epidermal morphogenesis. Nat. Rev. Mol.
Cell Biol. 12: 565-80.
Nekrasova, O.E., E.V. Amargo, Smith, W.O. Smith, J. Chen, G.E. Kreitzer, and K.J. Green. (2011). Desmosomal cadherins utilize distinct kinesins for
assembly into desmosomes. J. Cell Biol. 195: 1185-203.
Harmon, R.M., C.L. Simpson, J.L. Johnson, J.L. Koetsier, A. Dubash, N. Najor, O. Sarig, E. Sprecher, and K.J. Green. (2013). Desmoglein-1/Erbin
interaction suppresses Erk activation to support epidermal differentiation. J. Clin. Invest. 123: 1556-70. PMC3613912.
Dubash, A.D., J.L. Koetsier, E.V. Amargo, N.A. Najor, R.H. Harmon, and K.J. Green. (2013). The GEF Bcr activates RhoA/MAL signaling in keratinocytes
to promote keratinocyte differentiation via Desmoglein-1. J. Cell Biol. 202: 653-66. PMC3747303.
Nekrasova, O. and K.J. Green (2013). Desmosome assembly and dynamics. Trends in Cell Biol. 23: 537-46.
Samuelov, L., O. Sarig R.M. Harmon, D. Rapaport, A. Ishida-Yamamoto, O. Isakov, J.L. Koetsier, A.Gat, I. Goldberg, R. Bergman, R. Spiegel, O. Eytan, S.
Geller, S. Peleg, N. Shomron, C.S.M. Goh, N. J. Wilson, F.J.D. Smith, E. Pohler, M.A. Simpson, W.H. I. McLean, A.D. Irvine, M. Horowitz, J.A. McGrath,
K.J. Green* and E. Sprecher*. (2013). Desmoglein 1 membranal deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat.
Genet. 45: 1244-8. (*Co-corresponding authors).
Patel, D, A. Dubash, and G. Kreitzer and K.J. Green (2014). Disease mutations in desmoplakin inhibit Cx43 membrane targeting mediated by
desmoplakin-EB1 interactions. J. Cell Biol. 206: 779-97.
Todorovic, V., J.L. Koetsier, L.M. Godsel and K.J. Green (2014). Plakophilin 3 mediates Rap1-dependent desmosome assembly and adherens junction
maturation. Mol. Biol. Cell. Epub Sept 10, 2014.
Acknowledgment of Support
The ESDR recognises the support of Celgene in making possible the 2015 Celgene ESDR Guest Lecture.
27
Time: 17.00-18.30
Chairs: Christoph Schlapbach, Mona Ståhle, Kerstin Steinbrink
Concurrent talks are 8 minutes plus 2 minutes discussion.
17.00-17.10
Human skin harbours a resident T cell subset with rapid, innate-like responsiveness: a new perspective on tissue immunesurveillance
R Woolf, O Nussbaumer and A Hayday Department of Immunobiology, King’s College London, United Kingdom
17.10-17.20
Human T-cell Leukemia Virus type 1 can modulate TLR-induced dendritic cells activation via C-Type lectin receptors
T Shimauchi,1 F Blanchet,1 K Finsterbusch,1 M Czubala,1 T Easter,1 K Ladell,2 D Price,2 C Bangham,3 Y Tokura4 and V Piguet1
1
Department of Dermatology & Wound Healing, Institute of Infection & Immunity, Cardiff University School of Medicine, Cardiff,
United Kingdom, 2Institute of Infection & Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, 3Section of
Immunology, Imperial College London Wright-Fleming Institute, London, United Kingdom and 4Department of Dermatology,
Hamamatsu University School of Medicine, Hamamatsu, Japan
17.20-17.30
The pruritus- and TH2-associated cytokine interleukin-31 promotes growth of sensory nerves
M Feld,1 R Garcia,2 S Katayama,3 G Muirhead,4 O Sergeeva,5 S Tsoka,4 J Kere,3 S Dillon,2 M Steinhoff6 and B Homey1 1Dermatology,
HHU, Düsseldorf, Germany, 2ZymoGenetics, Seattle, WA, 3Biosciences, Karolinska Institutet, Huddinge, Sweden, 4Informatics, King’s
College, London, United Kingdom, 5Neurophysiology, HHU, Düsseldorf, Germany and 6Dermatology, UCD, Dublin, Ireland
17.30-17.40
Innate immune signal triggered co-factor dependent anaphylaxis is mediated by TLR ligation
F Wölbing,2 S Kaesler,1 W Kempf,2 A Umbach,3 Y Skabytska,1 F Lang,3 P Yu,4 D Vöhringer,5 M Röcken1 and T Biedermann2
1
Dermatology, Eberhard Karls University Tübingen, Germany, 2Dermatology, Technical University Munich, Germany, 3Physiology,
Eberhard Karls University Tübingen, Germany, 4Institute of Immunology, Philipps-University Marburg, Germany
17.40-17.50
Transforming Growth Factor Beta Induces a SAMHD1-independent post-entry restriction to HIV-1 infection of immature
langerhans cells
M Czubala,1 M Ivory,1 F Blanchet2 and V Piguet1 1Infection and Immunity, Cardiff University, Cardiff, United Kingdom and 25UMR5236
CNRS, UM1,UM2, CPBS, Montpellier, France
17.50-18.00
Sensory fibers drive IL-23 from CD301b+ dermal dendritic cell to drive cutaneous host defense against Candida albicans
infection
SW Kashem and D Kaplan Dermatology, University of Minnesota, Minneapolis, USA
18.00-18.10
Keratinocytes play an essential role on epicutaneous Staphylococcus aureus infection through MyD88
S Nakagawa,1 Y Nakamura,1 Y Katayama,1 G Nunez2 and H Matsue1 1Dermatology, Chiba University, Chiba City, Japan and 2Pathology
and Comprehensive Cancer Center, University of Michigan, Ann Arbor, USA
18.10-18.20
Aryl hydrocarbon receptor activation at keratinocyte leads to atopic dermatitis-like lesion via artemin induction
T Hidaka,1 E Ogawa,2 E Kobayashi,1 T Suzuki,1 T Fujimura,1 S Aiba,3 R Okuyama2 and M Yamamoto1 1Medical Biochem, Tohoku Univ,
Sendai, Japan, 2Dermatol, Shinshu Univ, Matsumoto, Japan and 3Dermatol, Tohoku Univ, Sendai, Japan
18.20-18.30
Endothelial cell junctions are tightened by regulatory T cells via induction of a cAMP, VE-cadherin dependent mechanism,
leading to reduced inflammation in contact hypersensitivity reactions
S Ring, A Enk and K Mahnke University Hospital Heidelberg, Heidelberg, Germany
28
Time: 17.00-18.30
Room: Diamond Room
Chairs: Salvador Aznar Benitah, Sabine Eming, Matthew Hardman
17.00-17.10
Atypical Kinase C balances stem cell renewal and differentiation through the tumor suppressor Lethal Giant Larvae (Lgl)
S Vorhagen,1 F Tellkamp,2 M Fink,1 M Leitges3 and CM Niessen1 1Department of Dermatology / CECAD, Cologne, Germany, 2Center
for Molecular Medicine, Cologne, Germany and 3Biotechnology Centre, University of Oslo, Norway
17.10-17.20
Ceramide synthase 4 affects hair follicle cycling and stem cell maintenance
F Peters, S Vorhagen, S Brodesser, K Jakobshagen, JC Brüning, CM Niessen and M Krönke University of Cologne, Cologne, Germany
17.20-17.30
Dominant negative mutation of Sox18 inhibits normal dermal papilla development during embryogenesis and regeneration
RM Villani,1 S Hodgson,2 J Legrand,2 J Greaney,1 H Wong,2 C Pichol-Thievend,3 C Adolphe,3 B Wainwright,3 M Francois3 and
K Khosrotehrani1 1Diamantina Institute, University of QLD, Brisbane, QLD, Australia, 2UQCCR, University of QLD, Brisbane, QLD,
Australia and 3IMB, University of QLD, Brisbane, QLD, Australia
17.30-17.40
Suppression of Neutrophil-Mediated Tissue Damage – A Novel Skill of Mesenchymal Stem Cells
D Jiang,1 J Muschhammer,1 Y Qi,1 A Kügler,1 JC de Vries,1 M Saffarzadeh,2 A Sindrilaru,1 M Wlaschek,1 KT Preissner2 and
K Scharffetter-Kochanek1 1Department of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany and 2Institute of
Biochemistry, Justus Liebig University Giessen, Giessen, Germany
17.40-17.50
Plasmacytoid dendritic cells is a key player during the initiation phase of alopecia areata in C3H/HeJ mouse
T Ito, T Suzuki, A Funakoshi, T Fujiyama and Y Tokura Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan
17.50-18.00
Development of myelinated and non-myelinated sensory nerve fibers in reinnervated human skin promotes maturation of mast
cells from resident progenitor cells
J Chéret,1 L Ponce,1 R Clayton,3 C Le Gall-Ianotto,2 L Misery,2 M Bertolini1 and R Paus3 1University of Münster, Germany, 2University
of Western Brittany, Brest, France and 3University of Manchester, United Kingdom
18.00-18.10
Keeping in touch with autophagy – a mouse model with Atg7-deficient Merkel cells
S Sukseree, H Rossiter, E Tschachler and L Eckhart Department of Dermatology, Medical University of Vienna, Vienna, Austria
18.10-18.20
Lrig1 and CD44v3 expression in human folliculosebaceous unit
L Barnes,1 J Pünchera,1 J Saurat2 and G Kaya1 1University Hospital of Geneva, Dermatology, University of Geneva, Switzerland and
2
Swiss Centre for Human Applied Toxicology, University of Geneva, Switzerland
18.20-18.30
Expression map of three distinct skin fibroblast populations isolated from human skin
H Topouzi and CA Higgins Bioengineering, Imperial College London, United Kingdom
29
Time: 17.00-18.30
Chairs: Mark Berneburg, Eugene Healy, David Hill
17.00-17.10
Vasoactive intestinal peptide (VIP) is a novel, complex neuroendocrine regulator of human HF melanocyte biology in situ
M Bertolini,1 M Bähr,1 M Sulk,1 L Ponce,1 Y Uchida,1 J Chéret,1 K Loser,1 T Bíró,2 DJ Tobin3 and R Paus4 1Dermatology, University of
Münster, Lübeck, Germany, 2Immunology and Physiology, University of Debrecen, Debrecen, Hungary, 3Centre for Skin Sciences,
Faculty of Life Sciences, University of Bradford, United Kingdom and 4Centre for Dermatology Research, Institute of Inflammation
and Repair, University of Manchester, United Kingdom
17.10-17.20
A genome-wide association study in Korean women identifies susceptibility loci for Tanning phenotype
Y Chang,1 H Lee,2 S Park,4 J Shin,2 M Chang,1 Y Shin,3 H Jung,2 C Kim,2 J Lee2 and Y Lee2 1LG Household and Healthcare, Daejeon,
Republic of Korea, 2Department of Dermatology, Chungnam National University, Daejeon, Republic of Korea, 3Theragen-Etex Bio
Institute, Advanced Institute of Convergence Technology, Suwon-si, Republic of Korea and 4Gyeryong public health center, Gyeryong,
Republic of Korea
17.20-17.30
Emerging role of polyfunctional CXCR3+/CCR6+ effector memory T cells in vitiligo
J Seneschal, A Darrigade, B Dessarthe, C Vernisse, J Rambert, F Lucchese, N Boukhedouni, A Taieb, K Ezzedine and K Boniface
Dermatology, Bordeaux University, Bordeaux, France
17.30-17.40
Transcriptional analysis of vitiligo skins reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo
patients
C Regazzetti,1 F Joly,2 C Marty,2 M Rivier,2 B Mehul,2 P Reiniche,2 C Mounier,2 R Ballotti,1 J Voegel2 and T Passeron1 1INSERM, Nice,
France and 2Galderma, Sophia-Antipolis, France
17.40-17.50
Autophagy deficient mouse melanocytes display a senescence associated secretory phenotype (SASP) and ER stress after UV
exposure
C Ni,1 M Narzt,1 I Nagelreiter,2 L Larue,3 H Rossiter,1 E Tschachler1 and F Gruber1 1Dermatology, Medical University of Vienna,
Austria, 2Christian Doppler Laboratory for Biotechnology of Skin Aging, Vienna, Austria and 3Institut Curie, Orsay, France
17.50-18.00
Light-independent pro-inflammatory and pro-oxidant effects of purified human hair melanins on keratinocyte cell cultures
S Lembo,1 A Napolitano,2 R Di Caprio,1 L Panzella,2 R Micillo,2 A Balato1 and G Monfrecola1 1Dermatology Unit, Department of Clinical
Medicine and Surgery, University of Naples Federico II, Naples, Italy and 2Department of Organic Chemistry and Biochemistry,
University of Naples Federico II, Naples, Italy
18.00-18.10
UV-induced 6-4 photoproducts block DNA replication and activate the ATR-Chk1 pathway
M Kawasumi,1 K Hung,1 J Sidorova2 and P Nghiem1 1Medicine/Dermatology, University of Washington, Seattle, USA and 2Pathology,
University of Washington, Seattle, USA
18.10-18.20
UVB irradiation induces HMGB1 in keratinocytes without causing apoptosis
K Torii and A Morita Geriatric & Environmental Dermatology, Nagoya City University, Grad School of Medical Science, Nagoya, Japan
18.20-18.30
Intensity of oxidant stimulus, inflammation and cell senescence: possible implication in photoaging process
S Briganti, E Flori and M Picardo Laboratory of Cutaneous Physiopathology and CIRM, San Gallicano Dermatologic Institute, IRCCS,
Rome, Italy
30
FRIDAY
31
Date: Friday 11 September 2015
Time: 08.30-09.30
Chair: Alexander Enk (Heidelberg)
PROGRAM
08.30-08.50
New European guidelines on the use of IVIg: indications, therapy management and mode of action
Alexander Enk (Heidelberg)
08.50-09.10
Management of dermatomyositis and the importance of high-dose intravenous immunoglobulins
Cord Sunderkötter (Münster)
09.10-09.30
Non-receptor-mediated anti-inflammatory effects of IgG
Ralf Ludwig (Lübeck)
This educational symposium is supported by Biotest.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
32
Cytokine Signalling in Psoriasis: Extracellular and Intracellular
Therapeutic Targets
Time: 08.30-09.30
PROGRAM
08.30-08.40
Introduction and Overview of the Immunopathogenesis of Psoriasis
Peter van de Kerkhof (The Netherlands)
08.40-09.00
Therapeutic Cytokine Targeting – Intracellular and Extracellular Pathways
Frank Nestle (United Kingdom)
09.00-09.20
Emerging Data on the Mechanisms of Efficacy of JAK Inhibition
James G Krueger (USA)
09.20-09.30
Q&A
This educational symposium is supported by Pfizer.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
33
Time: 08.30-09.30
Room: Diamond Room
PROGRAM
08.30-08.35
Introduction
Martin Steinhoff (Ireland), Alison Layton (UK)
08.35-08.50
Current Knowledge on Innate Immunity in Acne & Rosacea
Anna Di Nardo (USA)
08.50-09.05
Unrevealing the Anti-inflammatory Properties of Ivermectin
Valérie Julia (Galderma R&D Sophia-Antipolis, France)
09.05-09.20
Presentation of the Galderma Acne & Rosacea Research Awardees
Alison Layton (UK)
09.20-09.30
Closing Remarks
Martin Steinhoff (Ireland)
This educational symposium is supported by Galderma.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
34
2015 ESDR Guest Lecture
Mechanisms Regulating Tumor Heterogeneity in Skin Cancers
Time: 9.30-10.00
Introduced by: Salvador Aznar Benitah
Cédric Blanpain, MD, PhD
Principal Investigator, Blanpain Lab
Interdisciplinary Research Institute
Université Libre de Bruxelles
Brussels, Belgium
Cédric Blanpain graduated as a Medical Doctor (1995), received his PhD
in Medical Sciences (2001) and was board certified in internal medicine
(2002) at the Université Libre de Bruxelles (ULB), Belgium. Cedric
performed a postdoctoral training in the laboratory of Elaine Fuchs, at
the Rockefeller University, New York, USA from 2002 to 2006.
Cédric Blanpain is full professor of Stem Cell and Development Biology
and investigator of the WELBIO (Walloon Excellence in Life science and
Biotechnology) at the IRIBHM, Université Libre de Bruxelles (ULB). His
research group is studying the mechanism regulating stem cell fate
decision during embryonic development, tissue homeostasis and repair
as well as the implication of stem cells during cancer initiation and
growth.
Cédric Blanpain received several prestigious awards and fellowships
including the career development award of the HFSP, EMBO young
investigator, ERC starting grant, Outstanding Young Investigator Award of
the International Society of Stem Cell Research (ISSCR) and is an EMBO
member since 2012.
Lescroart F, Chabab S, Lin X, Rulands S, Paulissen C, Rodolosse A, Auer H, Achouri Y, Dubois C, Bondue A, Simons BD, Blanpain C.
Early lineage restriction in temporally distinct populations of Mesp1 progenitors during mammalian heart development.
Nat Cell Biol. 2014 Sep;16(9):829-40. doi: 10.1038/ncb3024. Epub 2014 Aug 24.
Blanpain C, Fuchs E.
Stem cell plasticity. Plasticity of epithelial stem cells in tissue regeneration.
Science. 2014 Jun 13;344(6189):1242281. doi: 10.1126/science.1242281. Epub 2014 Jun 12. Review.
Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, Delatte B, Caauwe A, Lenglez S, Nkusi E, Brohée S, Salmon I, Dubois C, del
Marmol V, Fuks F, Beck B, Blanpain C.
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.
Nature. 2014 Jul 10;511(7508):246-50. doi: 10.1038/nature13305. Epub 2014 Jun 8.
Beck B, Blanpain C.
Unravelling cancer stem cell potential.
Nat Rev Cancer. 2013 Oct;13(10):727-38. doi: 10.1038/nrc3597.
Blanpain C, Simons BD.
Unravelling stem cell dynamics by lineage tracing.
Nat Rev Mol Cell Biol. 2013 Aug;14(8):489-502. doi: 10.1038/nrm3625. Epub 2013 Jul 17. Review.
Sotiropoulou PA, Karambelas AE, Debaugnies M, Candi A, Bouwman P, Moers V, Revenco T, Rocha AS, Sekiguchi K, Jonkers J, Blanpain C.
BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny.
Genes Dev. 2013 Jan 1;27(1):39-51. doi: 10.1101/gad.206573.112. Epub 2012 Dec 27.
Lapouge G, Beck B, Nassar D, Dubois C, Dekoninck S, Blanpain C.
Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness.
EMBO J. 2012 Dec 12;31(24):4563-75. doi: 10.1038/emboj.2012.312. Epub 2012 Nov 27.
35
Plenary 2
Time: 10.00-11.15
Chairs: Zsuzsanna Bata-Csörgo, John McGrath, Maarten Vermeer
Plenary talks are 8 minutes plus 2 minutes discussion.
10.00-10.10
Skin type VII collagen acts as a tumour suppressor by regulating TGFβ and angiogenesis
V Martins,1 M Caley,1 K Moore,2 Z Szentpetery,1 S Marsh,1 DF Murrell,3 V-M Kähäri,4 J McGrath,5 J Marshall2 and E O’Toole1 1Centre
for Cell Biology & Cutaneous Research, Barts & the London School of Medicine & Dentistry, United Kingdom, 2Barts Cancer
Institute, Barts & the London School of Medicine and Dentistry, United Kingdom, 3Dermatology, University of New South Wales,
Sydney, Australia, 4Dermatology, University of Turku, Finland 5St John’s Inst of Dermatology, Kings College London, United Kingdom
10.10-10.20
Murine macrophage NADPH oxidase controls wound healing
A Kügler,1 S Schatz,1 S Vander Beken,1 D Jiang,1 T Peters,1 L Schneider,1 A Rück,2 B De Geest,3 K Scharffetter-Kochanek1 and
A Sindrilaru1 1Dermatology and Allergic Diseases, University of Ulm, Germany, 2Core Facility for Confocal and Multiphoton
Microscopy, University of Ulm, Germany and 3Department of Pharmaceutics, University of Ghent, Belgium
10.20-10.30
Commensal microbe-derived short chain fatty acids induce cutaneous regulatory T cells in mice
A Schwarz, A Bruhs and T Schwarz Dermatology, University Clinic Kiel, Germany
10.30-10.40
IL-17 produced by group 3 innate lymphoid cells (ILC3) and γδT cells is pivotal for host defense against epicutaneous candidiasis
via neutrophil activation
MT Iwasawa,1 Y Nakamura,1 S Wakabayashi,1 S Saijo2 and H Matsue1 1Dermatology, Chiba University, Japan and 2Medical Mycology
Research Center, Chiba University, Japan
10.40-10.50
NUAK2 amplification coupled with PTEN deficiency promote melanoma development via CDK activation
T Namiki,1 T Yaguchi,2 K Nakamura,2 M Kawaguchi,3 A Tanemura,4 I Katayama,4 H Yokozeki,1 Y Kawakami2 and V Hearing3
1
Dermatology, Tokyo Medical and Dental University, Tokyo, Japan, 2Division of Cellular Signaling, Keio University School of Medicine,
Institute for Advanced Medical Research, Tokyo, Japan, 3Laboratory of Cell Biology, National Cancer Institute, Bethesda, MD and
4
Dermatology, Osaka University Graduate School of Medicine, Osaka, Japan
10.50-11.00
Herpes zoster, acute cardiovascular events and the role of zoster vaccination
C Minassian, S Thomas, L Smeeth, I Douglas, R Brauer and S Langan Faculty of Epidemiology and Population Health, London School
of Hygiene and Tropical Medicine, London, United Kingdom
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
36
Time: 11.15-11.30
Chairs: Zsuzsanna Bata-Csörgo, John McGrath, Maarten Vermeer
Introduction
The Come See My Poster sessions take place at directly after Plenary 1 and Plenary 2. These sessions give an opportunity for presenting
selected authors of highly ranked posters to give a brief one-minute introduction to their work displayed at the meeting.
Poster
261
The microvesicular miRNome of senescent human fibroblasts
L Terlecki-Zaniewicz,1 I Lämmermann,1 H Dellago,1 R Weinmüllner,1 M Hackl2 and J Grillari1 1Biotechnology, University of Nat Res
and Life Science, Vienna, Vienna, Austria and 2TAmiRNA GmbH, Vienna, Austria
259
p38 Map kinase compensates barrier dysfunction caused by loss of epidermal insulin/IGF-1 signaling
E Wachsmuth,1 SY Aghdam,2 MD Akyuz,1 C Günschmann,1 JC Bruning3 and CM Niessen1 1Department of Dermatology, University of
Cologne, Germany, 2University of Wisconsin, Madison, WI and 3Center for Endocrinology, Diabetes and Preventive Medicine (CEDP),
University hospital of Cologne, Germany
325
New plectinopathy affecting only skin from plectin isoform 1a deficiency
MF Jonkman,1 K Gostynska,1 H Pas,1 AM Pasmooij,1 MJ Castañón2 and G Wiche2 1Dermatology, University Medical Centre Groningen,
Groningen, Netherlands and 2Biochemistry and Cell Biology, University of Vienna, Austria
331
Insulin and Insulin-like growth factor-1 Can Modulate the Phosphoinositide-3-kinase / Akt/ FoxO1 Pathway in SZ95 Sebocytes
Y Mirdamadi,1 A Thielitz,1 CC Zouboulis,2 U Bommhardt,3 S Quist1 and H Gollnick1 1Department of Dermatology and Venereology,
Otto-von-Guericke-University, Magdeburg, Germany, 2Departments of Dermatology, Venereology, Allergology and Immunology,
Dessau Medical Center, Dessau, Germany and 3Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University,
Magdeburg, Germany
377
MFG-E8 promotes mesenchymal stem cells-induced angiogenesis
K Yamada, A Uchiyama, S Ogino, B Perera, Y Yokoyama, Y Takeuchi, O Ishikawa and S Motegi Gunma University, Maebashi, Japan
378
Role of cortical actin disorganization in keratinocyte proliferation in psoriasis
S Lee,1 H Hong,1 S Kim2 and J Kim1 1Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and
Technology, Daejeon, Republic of Korea and 2Department of Dermatology, College of Medicine, Yonsei University, Seoul, Republic of
Korea
425
Acute Graft-versus-Host-Disease likely results of skin resident T cells reaction to newly generated dendritic cells from
engrafted stem cells
TR Matos, KF Lima, CP Elco, A Gehad, JE Teague, TS Kupper and R Clark Brigham and Women’s Hospital and Harvard Medical
School, Boston, MA
428
Expansion of circulating CD49b+LAG3+ type 1 regulatory T cells in human skin chronic graft-versus-host disease
A de Masson,1 H Le Buanec,1 M Robin,2 M Bagot,1 A Bensussan,1 G Socié2 and J Bouaziz1 1INSERM U976, Paris, France and 2Saint
Louis Hospital, Paris, France
483
The relationship between pigmentation level and CD4+, CD8+ and CD20+ lymphocytes in primary cutaneous melanomas
AA Brozyna,1 W Jozwicki1 and AT Slominski2 1Dept. of Tumor Pathology and Pathomorphology, Oncology Centre-Lukaszczyk
Memorial Hospital, Rydygier Collegium Medicum, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland and 2Dept. of
Dermatology, University of Alabama at Birmingham, Birmingham, AL
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
37
Understanding Lupus: The importance of the Ubiquitination Pathway
Time: 13.00-14.30
Key Learning Objectives
Understand the molecular etiology and genetic risk factors leading to Lupus
Understand the relevant autoantigens driving disease pathology
Understand the current clinical research efforts targeting the treatment of Lupus
This symposium is open to all registered ESDR delegates. Lunch boxes will be provided.
PROGRAM
13.00-13.10
Welcome & Introduction to Understanding Lupus
Michel Gilliet (Lausanne, Switzerland)
13.10-13.30
Dissecting the Molecular Pathways Conferring the Risk of Lupus
Myles Lewis (London, United Kingdom)
13.30-13.35
Q&A
13.35-13.55
Immunopathogenic Mechanisms in Lupus
Claudia Günther (Dresden, Germany)
13.55-14.00
Q&A
14.00-14.20
Developments in Targeted Therapy for Lupus
Peter Schafer (New York, USA)
14.00-14.25
Q&A
14.25-14.30
Summary and Close
Michel Gilliet (Lausanne, Switzerland)
This educational symposium is supported by Celgene.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
38
Time: 13.30-14.30
Room: Diamond Room
Chair: David Kelsell (London, UK)
PROGRAM
13.30-13.55
DECIPHER: A Platform for Discovery and Diagnosis in Rare Disease
Helen Firth (Cambridge, UK)
13.55-14.20
Clinical and Genetic Variability of Keratodermas
Edel O’Toole (London, UK)
14.20-14.30
Summary and Future Perspectives
David Kelsell (London, UK)
This educational symposium is supported by the ESDR.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
39
2015 René Touraine Guest Lecture
Mast Cells - Can’t Live with Them, Can’t Live without Them
Time: 14.30-15.00
Introduced by: Thomas Luger (Münster, Germany)
Marcus Maurer, MD
Professor of Dermatology and Allergy
Director of Research
Dept of Dermatology and Allergy
Charité - Universitätsmedizin Berlin
Germany
Professor for Dermatology and Allergy; Director of Research at the
Department of Dermatology and Allergy; Associate Director of the
Allergie-Centrum-Charité; Head of the Specialty Clinics for Urticaria,
Mastocytosis, Pruritus and Angioedema and the Dermatological
Allergology Lab; trained in experimental pathology at the Beth Israel
Deaconess Hospital and Harvard Medical School in Boston (1995-98);
Board certification for Dermatology (2000) and Allergology (2003).
Habilitation (“Why do we have mast cells?“) at the University of Mainz (2003).
Head of urticaria network e.V. (UNEV). Coordinator of the National
Priority Programme “Physiological functions of mast cells”. Head of
GA²LEN Taskforce on urticaria and the EU COST programme “Mast cells
and basophils”.
Board member for ECARF in German Foundation for Pollen Information
Service.
Siebenhaar, F., Metz, M., and Maurer, M.: Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo
carcinogenesis in a Kit-dependent mouse model. Exp. Dermatol. 2014: 23; 159-164.
Maurer, M., Rosén, K., Hsie, H. J., Saini, S., Grattan, C., Gimenéz-Arnau, A., Agarwal, S., Doyle, R., Canvin, J., Kaplan, A., and Casale, T.: Omalizumab
for the treatment of chronic idiopathic or spontaneous urticaria. New Engl. J. Med. 2013: 368; 924-935.
Dudeck, A., Sünder, C., Lopez Kostka, S., von Stebut, E.*, and Maurer, M.*: Mast cells promote Th1 and Th17 responses by modulating dendritic cell
maturation and function. Eur. J. Immunol. 2011: 41; 1883-1893.
Altrichter, S.*, Peter, H.-J.*, Pisarevskaja, D., Metz, M., Martus, P., and Maurer, M.: IgE mediated autoallergy against thyroid peroxidase – a novel
pathomechanism of chronic spontaneous urticaria? PLoS ONE 2011: 6; e14794.
Weller, K., Foitzik, F., Paus, R., Syska, W., and Maurer, M.: Mast cells are required for normal healing of skin wounds in mice. FASEB J. 2006: 20;
2366-2368.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
40
Time: 15.00-16.30
Chairs: Jonathan Barker, Andrea Chiricozzi, Marieke Seyger
15.00-15.10
IκBζ plays an important role in the pathogenesis of psoriasis by mediating IL-17A-driven effects
C Johansen,1 P Ommen,1 T Bertelsen,1 H Vinter,1 S Hailfinger,2 S Lorscheid,2 K Schulze-Osthoff2 and L Iversen1 1Department of
Dermatology, Aarhus University Hospital, Aarhus, Denmark and 2Department of Molecular Medicine, Eberhard Karls University,
Tübingen, Germany
15.10-15.20
Skin-mediated promotion of thrombosis is abrogated following IL-23/IL-17 inhibition or IL-6 deletion in mouse models of
psoriasis
J Golden,1 Y Fritz,1 Y Wang,2 Y Li,1 D Simon,2 TS McCormick1 and NL Ward1 1Dermatology, Case Western Reserve University,
Cleveland, USA and 2Cardiovascular Medicine, Case Western Reserve University, Cleveland, USA
15.20-15.30
Langerhans cells migrate to lymph nodes with increased number in mice with Stat3 activation in keratinocytes and are essential
for development of psoriasis-like lesion
K Nakajima,2 S Kataoka,2 M Yamamoto,2 B Malissen1 and S Sano2 1Centre d’Immunologie de Marseille-Luminy, UM2 Aix-Marseille
Université, Marseille, France and 2Department of Dermatology, Kochi Medical School, Nankoku, Japan
15.30-15.40
Interleukin (IL)-26 overexpressed in psoriatic skin has antimicrobial and pro-inflammatory functions
J Di Domizio,2 S Meller1 and M Gilliet2 1Heinrich-Heine-University, Duesseldorf, Germany and 2University Hospital of Lausanne,
Lausanne, Switzerland
15.40-15.50
Programmed cell death-ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from PD-1hi T cells
J Kim,1 Y Choi,1 B Lee,2 S Park,3 H Kim,4 Y Sung,5 S Kim6 and E Shin1 1Laboratory of Immunology and Infectious Diseases, Graduate
School of Medical Science and Engineering, KAIST, Daejeon, Republic of Korea, 2Genexine, Inc., Seongnam, Republic of Korea,
3
Laboratory of Translational Immunology & Vaccinology, Graduate School of Medical Science and Engineering, KAIST, Daejeon,
Republic of Korea, 4Dept of Environmental Medical Biology, Institute of Tropical Medicine, Yonsei University College of Medicine,
Seoul, Republic of Korea, 5Division of Integrative Biosciences and Biotechnology, Pohang University of Science & Technology,
Pohang, Republic of Korea and 6Dept of Dermatology & Cutaneous Biology Research Institute, Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, Republic of Korea
15.50-16.00
Innate stimulus triggering preferential Th17 response in HLA-Cw6+ gutatte psoriasis through skin-specific memory T cells,
epidermal cells, and Streptococcus pyogenes interaction
E Ruiz Romeu,2 M Ferran,1 M Sagristà,1 A Giménez-Arnau,1 A Celada,2 R Pujol1 and L Santamaria-Babi2 1Dermatology, IMAS,
Barcelona, Spain and 2Physiology and Immunology, University of Barcelona, Barcelona, Spain
16.00-16.10
Expanded αβ T cell clones are present in the healed lesions of psoriasis and likely represent the autoreactive T cells of origin
TR Matos,1 JT O’Malley,1 A Gehad,1 JE Teague,1 E Lowry,1 H Robins,3 TS Kupper,1 JG Krueger2 and R Clark1 1Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA, 2Rockefeller University, New York, NY and 3Adaptive Biotechnologies, Seattle, WA
16.10-16.20
The International Psoriasis Council Exome Chip Project: Exome arrays reveal known and novel coding variant associations
International Psoriasis Council Exome Chip Consortium1,2,3 (speaker: Nick Dand1) 1King’s College London, London, UK, 2ChristianAlbrechts-University, Kiel, Germany, 3University of Michigan Ann Arbor, Michigan, USA
16.20-16.30
Molecular diagnostics of psoriasis and eczema- a novel approach to establish personalised therapy
NV Garzorz,3 L Krause,1 F Lauffer,3 A Atenhan,2 J Thomas,2 FJ Theis,1 T Biedermann,3 C Schmidt-Weber,2 S Eyerich2 and K Eyerich3
1
Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany, 2Center of Allergy and Environment,
Technical University, Munich, Germany and 3Department of Dermatology and Allergy, Technical University Munich, Germany
41
Time: 15.00-16.30
Room: Diamond Room
Chairs: Kathy Green, Veli-Matti Kähäri, Edel O’Toole
15.00-15.10
A Hay-Wells syndrome mouse model reveals a crucial function for p63 in regulating skin mechanical integrity and thymic
stromal lymphopoietin levels
M Mollo,1 L Cirillo,1 JL Johnson,2 E Polishchuk,3 R Polishchuk,3 D Antonini4 and C Missero1 1CENIGE-Center for Genetic Engineering,
Naples, Italy, 2Pathology and Dermatology, Feinberg School of Medicine, Chicago, IL, 3Telethon Institute of Genetics and Medicine
(TIGEM), Naples, Italy and 4IRCCS SDN, Naples, Italy
15.10-15.20
iRHOM2 regulation of ADAM17 is a key regulator of epithelial growth factor signalling
MA Brooke, B Fell and D Kelsell Blizard Institute, Barts & The London School of Medicine & Dentistry, London, United Kingdom
15.20-15.30
The recessive mutation G2375R in human desmoplakin, associated with cardiac, skin and hair abnormalities, inhibits the binding
of desmoplakin to intermediate filaments
B Favre,1 N Begré,1 L Fontao2 and L Borradori1 1Clinical Research-Dermatology, Insel Hospital-University of Bern, Switzerland and
2
Dermatology, University Hospital of Geneva, Switzerland
15.30-15.40
Nuclear actin controls keratinocyte motility via transcriptional regulation of adhesive and cytoskeletal genes
AS Sharili and JT Connelly Centre for Cell Biology and Cutaneous Research, Queen Mary, University of London, United Kingdom
15.40-15.50
Collective endothelial cell migration is regulated by VE-cadherin endocytosis, adhesion, and cytoskeletal linkage
C Cadwell, B Nanes and A Kowalczyk Emory University, Atlanta, GA, USA
15.50-16.00
Plakophilin 1 is Essential for Desmosomal Adhesion and Survival
K Rietscher, A Wolf and MB Hatzfeld Institute of Molecular Medcine, Pathobiochemistry, Martin-Luther-University of Halle/Saale,
Halle/Saale, Germany
16.00-16.10
Classical cadherin mediated mechanotransduction in the regulation of tight junctions and desmosomes
M Rübsam,1 B Boggetti,1 J Xia,1 A Mertz2 and CM Niessen1 1Department of Dermatology; Center for Molecular Medicine Cologne;
Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne,
Germany and 2Department of Physics, Yale University, New Haven, CT, USA
16.10-16.20
Collagen XVII-laminin-332 interactions modulate keratinocyte motility
E Hoppe, L Bruckner-Tuderman, C Has and C Franzke Dermatology, University Freiburg Medical Center, Freiburg, Germany
16.20-16.30
In vivo restoration of type VII collagen expression in human-skin-graft mouse model upon antisense oligonucleotide-mediated
exon skipping
J Bremer,1 PC van den Akker,2 A Gostynski,1 MF Jonkman,1 A Aartsma-Rus3 and AM Pasmooij1 1Dermatology, University of
Groningen, University Medical Center Groningen, Netherlands, 2Genetics, University of Groningen, University Medical Center
Groningen, Netherlands and 3Human Genetics, University Medical Center Leiden, Netherlands
42
Time: 15.00-16.30
Chairs: Lionel Larue, Caterina Missero, Christian Posch
15.00-15.10
Mechanisms regulating HPV8-mediated tumorigenesis
X Ding,1 T Lucas,1 G Marcuzzi,2 H Pfister2 and S Eming1 1Department of Dermatology, University of Cologne, Germany and 2Institute
of Virology, University of Cologne, Germany
15.10-15.20
Th1 immunity controls malignant transformation by preventing loss of differentiation
H Braumüller, T Wieder, E Brenner and M Röcken University Medical Center Tübingen, Germany
15.20-15.30
Attenuation of human SCC malignancy by introduction of reprogramming factors
M Takaishi,1 M Tarutani,1 J Takeda2 and S Sano1 1Department of Dermatology, School of Medicine, Kochi University, Nankoku, Japan
and 2Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
15.30-15.40
Role of Xeroderma pigmentosum fibroblasts in squamous cell carcinoma cells invasion
SI Al-Qaraghuli, S Rouanet, C Gagioli, J Albrengues, M Goncalves-Maia, T Magnaldo and Y Gache Institute for research on cancer
and aging, Nice, France
15.40-15.50
MiR-203 is suppressed in poorly but not well-differentiated cutaneous squamous cell carcinomas and regulates the expression
of MYC oncogene
W Lohcharoenkal,1 M Harada,2 J Lovén,3 NX Landén,1 M Ståhle,1 E Sonkoly,1 M Arsenian-Henriksson,3 D Grandér2 and A Pivarcsi1
1
Unit of Dermatology, Karolinska Institutet, Stockholm, Sweden, 2Department of Oncology-Pathology, Karolinska Institutet,
Stockholm, Sweden and 3MTC, Karolinska Institutet, Stockholm, Sweden
15.50-16.00
B cells Promote Tumor Immunity against B16F10 Melanoma
T Kobayashi,1 T Matsushita,1 Y Hamaguchi,1 M Hasegawa,2 M Fujimoto3 and K Takehara1 1Department of Dermatology, Institute of
Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, 2Dermatology, University of Fukui, Fukui,
Japan and 3Dermatology, University of Tsukuba, Tsukuba, Japan
16.00-16.10
Dysregulation of soluble adenylyl cycase leads to melanocyte transformation
CA Nardin,1 M Park,2 A Bacchiocchi,3 R Halaban3 and J Zippin4 1Dermatologie, Centre Hospitalier Universitaire de Besancon,
Besancon, France, 2Dermatology, Albert Einstein College of Medicine, New York, USA, 3Dermatology, Yale University, New Haven,
USA and 4Meyer Cancer Center, Weill Cornell Medical Center, New York, USA
16.10-16.20
The role of argonaute protein 2 in cytokine-induced senescence of cancer cells
M Rentschler, Y Chen, H Braumüller, J Pahl, E Brenner, S Weidemann, T Wieder and M Röcken Dermatology, University Medical
Center Tübingen, Germany
16.20-16.30
Tumor cell-intrinsic PD-1 pathway effects promote Merkel cell carcinoma growth
C Posch,1 S Kleffel,1 MC Joubert,1 Q Zhan,2 S Fucaloro,1 M Thakuria,1 TS Kupper,1 GF Murphy2 and T Schatton1 1Dermatology,
Brigham and Women’s Hospital, Boston, USA and 2Pathology, Brigham and Women’s Hospital, Boston, USA
43
2015 Rudi Cormane Lecture
DCs, Tregs and Beyond: Lessons Learnt from the Skin Immune System
Time: 17.15-17.45
Introduced by: Mauro Picardo
Alexander Enk, MD
Chair, Department of Dermatology
Ruprecht Karls Universität
Heidelberg, Germany
Alexander H. Enk, M.D., is head of the Department of Dermatology at the
Ruprecht Karls Universität Heidelberg. He earned his medical degree at
the University of Münster, FRG in 1988. The same year, he started his
residency in dermatology at the Department of Dermatology in Mainz.
Subsequently, he left Germany for a research fellowship at the National
Institutes of Health, Dermatology Branch with Steve Katz from 1990-
1992, before returning to Germany and completing his residency in 1994
in Mainz.
Alexander Enk became Chair of the Department of Dermatology in
Heidelberg in 2004. His specialization is in immunodermatology and he
has co-authored more than 200 publications in peer reviewed journals.
He is also an elected member of the German Academy of Sciences
“Leopoldina”.
Currently Secretary and President-Elect of the German Dermatological
Association, Prof Enk is a former president of the ESDR and is a Board
member of the ISID. He is member of the ESDR, EADV, SID and German
Dermatological Society and is an honorary member of the JSID as well as
the Hungarian and Austrian dermatological societies.
Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by
repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222, 2000.
Jonuleit H, Schmitt E, Tüttenberg A, Stassen M, Knop J, Enk AH. Identification and functional characterization of human CD4+/CD25+ with regulatory
properties isolated from peripheral blood. J. Exp. Med. 193: 1285-1294, 2001.
Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: Human CD25+ regulatory T cells convey suppressor activity to
conventional CD4+ T helper cells. J. Exp. Med. 196:255-261, 2002.
Mahnke, K., Qian Y., Knop, J., Enk, A.H.. Dendritic cells, engineered to secrete a T-cell receptor mimick peptide, induce antigen-specific
immunosuppression in vivo. Nat. Biotechnol. 21:903-908, 2003.
Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold, Nawroth PP, Hess J, Angel P. RAGE signalling
sustains inflammation and promotes tumor development. J Exp Med. 2008 Feb 18/205(2):275-85.
Ring S, Enk AH, Mahnke K. ATP activates regulatory T Cells in vivo during contact hypersensitivity reactions. J Immunol. 2010 Apr 1; 184(7):3408-16
Döbel, T, Kunze, A., Tränkner K, Ludwig A., Schmitz, M, Enk A, Schäkel, K.FcγRIII (CD16) equips immature 6-sulfo LacNAc-expressing dendritic cells
(slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood 2013
44
SATURDAY
45
Date: Saturday 12 September 2015
Time: 08.30-09.30
PROGRAM
All talks are 15 minutes plus 5 minutes Q & A
08.30-08.50
Mitochondrial Dysfunction Across Skin Diseases
Johann Bauer (Salzburg)
08.50-09.10
Potential of Mitochondria-Targeting Peptides to Improve Mitochondrial Function
David A. Brown (USA)
09.10-09.30
Vitiligo as Possible Mitochondrial Disease
Mauro Picardo (Rome)
This educational symposium is supported by Stealth Biotherapeutics.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
46
Time: 08.30-09.30
Chair: Neil H Shear (Toronto)
PROGRAM
Each talk is 15 minutes and will be followed by 5 minutes discussion.
08.30-08.50
Biologics and Biosimilars: Why Structural Differences Matter
Roy Jefferis, MD, PhD (Professor Emeritus, School of Immunity and Infection, University of Birmingham, Birmingham, UK)
08.50-09.05
Structural Consistency of Adalimumab, A Glycosylated Monoclonal Antibody
Paul W Tebbey, PhD, MBA (Therapeutic Area Lead, Biotherapeutics, Global Medical Affairs, AbbVie Inc, Chicago, Illinois, USA)
09.05-09.25
Translating Structural Differences to Clinical Practice and Research
Neil H Shear, MD (Professor and Chief of Dermatology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada)
09.25-09.30
Q&A
This educational symposium is supported by Abbvie.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
47
Time: 08.30-9.30
Room: Diamond Room
Charles Institute Translational Dermatology Seminar Series
Sponsored by University College Dublin and Dublin Skin Charity (CDSCHC).
PROGRAM
08.30-08.35
Introduction and Overview
Martin Steinhoff (UCD Charles Institute of Dermatology, Dublin, Ireland)
08.35-09.00
TRP Ion channels as Regulators of Inflammation and Pruritus
Wolfgang Liedtke (Duke University, North Carolina, USA)
09.00-09.30
Central Mechanisms of Pruritus
Earl Carstens (University of California Davis, CA, USA)
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
.................................................................................................................................................................................................................................................
48
Time: 9.30-11.00
Chairs: Frank Nestle, Mauro Picardo
Introduction
Dermatology has numerous interfaces with basic science fields. Thus, a constant update in these areas is crucial for the further development
of dermatological research. The purpose of the Frontiers in Skin Biology and Dermatology lectures is to provide overviews about about
emerging fields in science including non-dermatological topics that are relevant for experimental and clinical dermatology. These talks are
principally intended as essential updates for “non-experts”. The Frontiers lectures are likely to be two of the most popular sessions at the
2015 ESDR meeting.
PROGRAM
09.30-10.00
Transcriptomic and Epigenomic Analyses to Understand Adult Stem Cell Function
Salvador Aznar Benitah (Barcelona)
10.00-10.30
Maintenance of the Mutualistic Interplay Between the Epithelial Barrier and the Gut Microbiota
Mathias Chamaillard (Lille)
10.30-11.00
Use of Lipidomics to Highlight Novel Therapeutic Targets
Michael J.O. Wakelam (Cambridge)
FACULTY
Salvador Aznar Benitah
Salvador Aznar Benitah obtained his Honours Degree in Biochemistry at McGill University (Montreal, Canada) in 1998. He then obtained
his PhD in Molecular Oncology at the Biomedical Research Institute in Madrid. In 2003 he moved to London as a postdoctoral fellow
to the laboratory of Prof. Fiona Watt at the London Research Institute (Cancer Research UK) where he became interested in studying
the behavior of adult stem cells. At the age of 32 he established is own lab at the Center for Genomic Regulation (CRG) in 2007 as a
Junior ICREA researcher.
In September 2012 Dr. Benitah was promoted to ICREA Research Professor, and in 2013 he moved his laboratory to the Institute for
Biomedical Research (IRB) in Barcelona as a Senior researcher. He has authored more than 45 papers in journals such as Science,
Nature, Nature Cell Biology,and Cell Stem Cell, among others. In 2013 he was awarded an ERC starting grant, and he has recently
been awarded in 2014 the Beug Foundation award for Metastasis Research, and the prestigious Banc Sabadell Investigator Award. In
2015 he has been appointed as a Foundation Botín Researcher.
Dr. Benitah’s lab aims at identifying and characterizing the molecular mechanisms underlying the function of adult stem cells,
in particular those that are responsible for the maintenance of stratified epithelia. The recent work of his lab has been mainly
focused in understanding how adult stem cells are spatiotemporally regulated, how they communicate with their local and systemic
environment, and how stem cell malfunction contributes to tissue ageing and cancer. In recent years and in close collaboration with
a team of clinicians at the Hospital Vall D’Hebron in Barcelona, his lab is developing a large project aimed at studying the molecular
mechanisms responsible for the metastatic spread of oral squamous cell carcinomas, to identify better prognostic and therapeutic
strategies against this aggressive type of tumor.
Mathias Chamaillard
The composition of gut microbial communities is controlled by co-evolutionarily conserved surveillance systems, including the Nodlike receptors. Our recent findings suggest that emerging, disease-predisposing dysbiosis can now be intentionally manipulated by
targeting the major Crohn’s disease-predisposing NOD2 gene and the related molecule NLRP6. However, the lack of a multi-level
approach with high spatial and temporal resolution biases our view of the bioactivity of the microbiota and the dynamics of the host’s
effector/regulatory immune network that maintain microbial symbiosis (Gastroenterology. 2013 Nov;145(5):1150-1).
Understanding the contribution that specific commensals make to impairing or failing to promote mucosal healing and how the host
coordinates bacterial symbiosis is urgently needed, in order to envision the development of more efficient therapeutic interventions.
To address this fundamental, challenging issue, we shall seek to identify: (i) biochemical, anatomical and immunological features of
commensals which overcome or preserve (either individually or as a whole organ) epithelial barrier function, and (ii) specific cellular
and molecular features through which NOD2 and NLRP6 shape a protective assembly of commensal lineages against intestinal
inflammation and tumorigenesis. These insights will be gained by combining germ-free and Cre-LoxP technologies with innovative
in vivo imaging, deep sequencing and mass spectrometry-based proteomics.The outputs of this integrated approach may challenge
dogmas on ancestral microbial-eukaryotic symbiosis, and have a broad impact on biomedical sciences worldwide.
Michael Wakelam
Michael Wakelam received a BSc in Medical Biochemistry in 1977 and a PhD in Biochemistry in 1980 from the University of
Birmingham. Following post-doctoral work at the University of Konstanz, Germany and Imperial College London he was appointed
to the faculty of the Biochemistry Department, Glasgow University in 1985; he moved to a full Professor position at the Institute for
Cancer Studies, University of Birmingham in 1993. In 2007 he became the Director of the Babraham Institute in Cambridge, he is an
Honorary Professor at Cambridge and Birmingham Universities and a visiting Professor at King’s College London. Dr Wakelam’s
research has made significant contributions to understanding the role and regulation of phospholipase D, to defining the importance
of the molecular structure of lipid species in their ability to function as messengers and also to the development of lipidomics
methodologies particularly for phosphoinositides. In addition to core BBSRC funding, his work is supported by programme grants
from the MRC, Cancer Research Technology and AstraZeneca.
49
2015 EADV Guest Lecture
Melanoma Genetics
Time: 11.00-11.30
Introduced by: Marcel Jonkman
Susana Puig, MD, PhD
Research Director
“Melanoma: Imaging, genetics and
immunology” at IDIBAPS
Barcelona, Spain
Susana Puig is the director of the research program “Melanoma:
Imaging, genetics and immunology” at the Biomedical Research Institute
August Pi I Sunyer (IDIBAPS). She serves as consultant dermatologist
at the Melanoma Unit, in the Dermatology Department of the Hospital
Clinic and as professor at the University of Barcelona. Special research
areas are melanoma and skin cancer focusing in different areas and their
clinical applications including imaging techniques for the in vivo noninvasive diagnosis, skin cancer susceptibility, carcinogenesis, genetics of
melanoma, melanoma immunology and therapy. She is devoted to teach
all over the world to translate to patient’s care innovation performed in
melanoma and skin cancer research. She has published more than 220
indexed papers, editor of several books and contributed with more than
30 book chapters. She is active member of international consortiums
as GenoMel, BioGenomel, M-skip and MelaNostrum dealing with
melanomas genetics and Board member of the International Dermoscopy
Society and the Confocal Working Group dedicated to imaging innovation.
Recent Publications
Salerni G, Carrera C, Lovatto L, Martí-Laborda RM, Isern G, Palou J, Alós L, Puig S, Malvehy J. Characterization of 1152 lesions excised over 10
years using total-body photography and digital dermatoscopy in the surveillance of patients at high risk for melanoma. J Am Acad Dermatol. 2012
Nov;67(5):836-45.
Puig-Butillé JA, Carrera C, Kumar R, Garcia-Casado Z, Badenas C, Aguilera P, Malvehy J, Nagore E, Puig S. Distribution of MC1R variants among
melanoma subtypes: p.R163Q is associated with Lentigo Maligna Melanoma in a Mediterranean population. Br J Dermatol. 2013 Oct;169(4):804-11.
Ogbah Z, Badenas C, Harland M, Puig-Butille JA, Elliot F, Bonifaci N, Guino E, Randerson-Moor J, Chan M, Iles MM, Glass D, Brown AA, Carrera C,
Kolm I, Bataille V, Spector TD, Malvehy J, Newton-Bishop J, Pujana MA, Bishop T, Puig S. Evaluation of PAX3 genetic variants and nevus number.
Pigment Cell Melanoma Res. Pigment Cell Melanoma Res. 2013 Sep;26(5):666-76
Shitara D, Ishioka P, Alonso-Pinedo Y, Palacios-Bejarano L, Carrera C, Malvehy J, Puig S. Shiny White Streaks: A Sign of Malignancy at Dermoscopy
of Pigmented Skin Lesions. Acta Derm Venereol. 2014 Mar;94(2):132-7.
Bennàssar A, Vilata A, Puig S, Malvehy J. Validation Of Fluorescent Confocal Microscopy Criteria And Histopathological Correlation For The Diagnosis
Of Basal Cell Carcinoma And Most Common Subtypes. Br J Dermatol. 2014 Feb;170(2):360-5.
Alarcon I, Carrera C, Palou J, Alos L, Malvehy J, Puig S. Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in
doubtful lesions. Br J Dermatol. 2014 Apr;170(4):802-8.
Puig-Butille JA, Escámez MJ, Garcia-Garcia F, Tell-Marti G, Fabra A, Martínez-Santamaría L, Badenas C, Aguilera P, Pevida M, Dopazo J, Del Río M,
Puig S. Capturing the biological impact of CDKN2A and MC1R genes as an early predisposing event in melanoma and non melanoma skin cancer.
Oncotarget. 2013 Jul;22(7):494-6.
Pozzobon FC, Puig-Butillé JA, González-Alvarez T, Carrera C, Aguilera P, Alos L, Badenas C, Grichnik JM, Malvehy J, Puig S. Dermoscopic criteria
associated with BRAF and NRAS mutation status in primary cutaneous melanoma. Br J Dermatol. 2014 Oct;171(4):754-9.
Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S. Increased prevalence of lung, breast, and pancreatic cancers in
addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling. J Am Acad
Dermatol. 2014 Nov;71(5):888-95.
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen
U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D. TERT Promoter Mutation Status as an Independent Prognostic Factor in
Cutaneous Melanoma. J Natl Cancer Inst. 2014 Sep 13;106(9).
50
Time: 13.00-14.00
Room: Diamond Room
Introduction
This ESDR Educational Session will look at funding available from the European Commission via the Horizon 2020 Program, with a focus on
Health related opportunities, as well as the European Research Council (ERC) and fellowships and doctoral training programs from the Marie
Skłodowska-Curie Actions.
PROGRAM
13.00-13.45
Greg Dow (QMUL, London)
13.45-14.00
Q&A
FACULTY
Greg Dow
Greg Dow has been working in EU funding since the beginning of FP7, when he worked for the UK Research Office (UKRO) in Brussels.
At UKRO, he advised UK universities on successful strategies for acquiring EU research funding, and also acted as National Contact
Point for the UK for the European Research Council. Since leaving Brussels in 2009, Greg has worked for both the Liverpool and
London School of Tropical Medicine, bringing in several successful EU grant proposals within Health research, including Marie-Curie
fellowships, ERC grants, large scale cooperation programme grants and grants from other EU funders such as IMI and the European
Agency for Health and Consumers. Since 2012, he has been working in the newly created EU Unit at Queen Mary University of London,
where he focuses on advising academics in preparing successful proposals for Horizon 2020, setting up contracts and managing
ongoing projects. He continues to work closely with UKRO and the network of National Contact Points to stay up to date with the latest
developments in EU research funding.
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
51
Time: 13.30-14.30
Chairs: Chris Griffiths, Martin Röcken
About Clinical Saturday Lectures
The main mission of the ESDR is to foster basic research in dermatology and skin biology. To increase the exchange between basic scientists
and clinicians at the annual meeting, the ESDR includes “Clinical Saturday Lectures” as part of the regular program. By offering Clinical
Saturday Lectures and industry sponsored symposia, the ESDR hopes to make the meeting as attractive for clinicians as it always has been
for basic scientists. The ESDR feels committed to satisfying the needs and interests of both scientists and clinicians. The dialogue and cross
fertilization between these two groups is essential for the future prosperous development of dermatology. Clinical Saturday 2015 is run in
association with the European Academy for Dermatology and Venereology (EADV).
PROGRAM
13.00-13.30
How to Recognize Revertant Skin in Epidermolysis Bullosa
Marcel Jonkman (Groningen, The Netherlands)
13.30-14.00
The Role of the Innate Immune System in Atopic Dermatitis
Tilo Biedermann (Munich, Germany)
14.00-14.30
New Therapeutic Perpectives for XPC and DNA Repair Disorders
Alain Taïeb (Bordeaux, France)
NOTES
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
..................................................................................................................................................................................................................................................
52
Time: 14.30-16.00
Chairs: Michael Hertl, Marjon Pasmooij, Errol Prens
14.30-14.40
Effective melanoma defense by turning tumor resident mast cells into T-cell recruiting immune sentinels
S Kaesler,1 Y Skabytska,1 F Wölbing,1 M Koeberle,1 W Kempf,1 T Volz,1 M Röcken2 and T Biedermann1 1Dermatology, TU Munich,
Germany and 2Dermatology, University of Tübingen, Germany
14.40-14.50
IL-17C, TNFα and IL-36 compensate for loss of IL-6 and identify novel signals facilitating the transition between uninvolved and
involved psoriasis skin
P Klenotic,1 Y Fritz,1 A Johnston,2 TS McCormick1 and NL Ward1 1Derm, Case Western Reserve University, Cleveland, OH and 2Derm,
University of Michigan, Ann Arbor, MI
14.50-15.00
Expansion of thymus-derived Tregs exhibiting a Th2-like phenotype is promoted in atopic dermatitis
V Moosbrugger-Martinz,1 CH Tripp,1 R Gruber,1 BE Clausen,2 D Finke,3 C Heufler,1 H Fiegl,4 M Schmuth1 and S Dubrac1 1Department
of Dermatology and Venereology, Medical University of Innsbruck, Austria, 2Institute for Molecular Medicine, University Medical
Center of the Johannes Gutenberg-University Mainz, Germany, 3Developmental Immunology, Department of Biomedicine, University
of Basel, Switzerland and 4Department of Gynecology and Obstetrics, Medical University of Innsbruck, Austria
15.00-15.10
Development and characterization of a compromised organotypic model mimicking Atopic Dermatitis
P Rouaud,1 D Boudier,1 L Marchand,1 V Barruche,1 S Bordes,1 H Coppin,2 M Roth2 and B Closs1 1R&D, SILAB, Saint Viance, France and
2
Centre de Physiopathologie de Toulouse Purpan, Inserm, U1043; CNRS, U5282, Université de Toulouse, Toulouse, France
15.10-15.20
STING Activation of Tumor Endothelial Cells Initiates Spontaneous and Therapeutic Antitumor Immunity
O Demaria,1 N Gestermann,1 J Di Domizio,1 O Gaide,1 D Speiser,3 RL Modlin2 and M Gilliet1 1Dermatology, CHUV, Lausanne,
Switzerland, 2Dermatology, David Geffen School of Medicine at University of California, Los Angeles, CA and 3Ludwig Cancer
Research, Lausanne, Switzerland
15.20-15.30
Intravenous immunoglobulin regulates anti-desmoglein 3 autoantibody production in B220- antibody-producing cells in mice
with pemphigus vulgaris
Y Kase,1 J Yamagami,2 N Wada,2 H Takahashi,2 S Koyasu3 and M Amagai2 1Central Research Laboratory, Japan Blood Products
Organization, Kobe, Japan, 2Department of Dermatology, Keio University School of Medicine, Tokyo, Japan and 3Center for
Integrative Medical Sciences, RIKEN, Yokohama, Japan
15.30-15.40
PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita
H Koga,1 A Recke,2 G Vidarsson,3 H Pas,4 MF Jonkman,4 D Zillikens2 and R Ludwig2 1Department of Dermatology, Kurume University
School of Medicine, Kurume, Japan, 2Institute of Experimental Dermatology, University of Lübeck, Germany, 3Department of
Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam,
Netherlands and 4Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, University of
Groningen, Netherlands
15.40-15.50
The soluble form of Fas Ligand plays a pivotal role in blister formation in pemphigus
R Lotti,1 A Strasser,2 A Marconi,1 L O’Reilly2 and C Pincelli1 1Laboratory of Cutanous Biology, University of Modena and Reggio Emilia,
Modena, Italy and 2Molecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC,
Australia
15.50-16.00
Keratin mutations cause TSLP upregulation: implications for itch in blistering skin disorders
TM Magin,2 V Kumar,2 M Behr,2 D Kiritsi,1 A Scheffschick,2 M Homberg,2 A Schwieger-Briel1 and L Bruckner-Tuderman1
1
Universitätshautklinik, Uni Freiburg, Freiburg, Germany and 2TRM & Biological Sciences, Uni Leipzig, Leipzig, Germany
53
Time: 14.30-16.00
Room: Diamond Room
Chairs: Martine Bagot, Menno de Rie, Dedee Murrell
14.30-14.40
Baseline Expression of T Cell Receptor Gamma-V Gene Family is Associated with High Levels of Response to Ixekizumab
Treatment in Psoriasis
JG Krueger,1 M Suarez-Farinas,1 A Beselin,2 D Ilo,2 R Hoffman,2 E Dow,2 E Nantz,2 L Nisenbaum,2 K Schroeder2 and R Higgs2
1
Rockefeller U., New York, USA and 2Lilly, Indianapolis, USA
14.40-14.50
A comprehensive omics assessment of etanercept therapy for psoriasis
A Foulkes,1 N Rattray,1 M Pirmohamed,4 R Goodacre,1 NJ Reynolds,5 MJ Donaldson,3 M Barnes,2 CE Griffiths1 and R Warren1
1
University of Manchester, United Kingdom, 2Centre for Translational Pharmacogenomics, Queen Mary University London, United
Kingdom, 3GlaxoSmithKline, Uxbridge, United Kingdom, 4The University of Liverpool, United Kingdom and 5Department of Cellular
Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
14.50-15.00
Screening for PsA in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & EARP
MC Karreman,1 A Weel,2 M van der Ven,1 M Vis,1 I Tchetverikov,3 M Wakkee,4 T Nijsten,4 J Hazes1 and J Luime1 1Rheumatology,
Erasmus University Hospital, Rotterdam, Netherlands, 2Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 3Rheumatology,
Albert Schweitzer Hospital, Dordrecht, Netherlands and 4Dermatology, Erasmus University Hospital, Rotterdam, Netherlands
15.00-15.10
Expression ability of RNAIII gene encoding δ-toxin in Staphylococcus aureus isolated from infant skin is associated with atopic
dermatitis development
Y Nakamura,1 Y Inoue,2 Y Katayama,1 G Nunez,3 N Shimojo2 and H Matsue1 1Dermatology, Chiba University, Chiba, Japan, 2Pediatrics,
Chiba University, Chiba, Japan and 3Pathology, University of Michigan, Ann Arbor, USA
15.10-15.20
A systematic review & meta-analysis on biomarkers for disease severity in atopic dermatitis
JL Thijs,1 T Krastev,1 S Weidinger,2 CF Buckens,3 M de Bruin-Weller,1 CA Bruijnzeel-Koomen,1 C Flohr4 and D Hijnen1 1Dermatology,
UMC Utrecht, Utrecht, Netherlands, 2Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus
Kiel, Germany, 3Radiology, UMC Utrecht, Netherlands and 4Paediatric Dermatology, St John’s Institute of Dermatology, Guy’s & St
Thomas’ Hospitals NHS Foundation Trust & King’s College, London, United Kingdom
15.20-15.30
Prospective controlled studies on the routine use of a novel multivariant ELISA for the diagnosis of autoimmune bullous diseases
N van Beek,1 C Dähnrich,2 N Hornig,2 S Lemcke,1 S Goletz,1 J Dworschak,1 D Zillikens,1 W Schlumberger,2 E Schmidt1 and
I Autoimmune Bullous Diseases Study Group3 1Department of Dermatology, University of Luebeck, Germany, 2Institute of
Experimental Immunology,Euroimmun AG, Luebeck, Germany and 3International Autoimmune Bullous Disease Study Group
15.30-15.40
Risk of Death in Bullous Pemphigoid: a Retrospective Database Study in Finland
A Försti,1 J Jokelainen,2 M Timonen3 and K Tasanen1 1Department of Dermatology, Oulu University Hospital, Finland, 2Unit of General
Practice, Oulu University Hospital, Finland and 3Institute of Health Sciences, University of Oulu, Finland
15.40-15.50
Cancer in neurofibromatosis 1
S Peltonen,1 E Uusitalo,2 M Rantanen,3 R Kallionpää,2 M Pöyhönen,4 J Leppävirta,1 J Pitkäniemi3 and J Peltonen2 1Department of
Dermatology, University of Turku and Turku University Hospital, Finland, 2Department of Cell Biology and Anatomy, University of
Turku, Finland, 3Finnish Cancer Registry, Helsinki, Finland and 4Helsinki University Hospital, Finland
15.50-16.00
Quantification of risk factors for postherpetic neuralgia in a cohort of herpes zoster patients
H Forbes, K Bhaskaran, S Thomas, L Smeeth, T Clayton, K Mansfield, C Minassian and S Langan Faculty of Epidemiology and
Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
54
Time: 14.30-16.00
Chairs: Alain Hovnanian, Veronica Kinsler, Peter Steijlen
14.30-14.40
Inducible expression of gasdermin A3 in the epidermis causes skin inflammation and hair cycle defect
H Lin, P Lin and L Yang Institute of Celluar and System Medicine, National Health Research Institutes, Miaoli County, Taiwan
14.40-14.50
Familial aplasia cutis congenita is caused by a defect in ribosome biogenesis
AG Marneros Dermatology, Massachusetts General Hospital/Harvard Medical School, Charlestown, USA
14.50-15.00
Molecular diagnostics of somatic overgrowth syndromes: The emergent concept of PIK3CA-related overgrowth spectrum (PROS)
L Youssefian,2 H Vahidnezhad,3 Q Li1 and J Uitto1 1Thomas Jefferson University, Philadelphia, USA, 2Tehran University of Medical
Sciences, Tehran, Iran and 3Pasteur Institute of Iran, Tehran, Iran
15.00-15.10
Postzygotic activating mutations of MTOR cause hypomelanosis of Ito with brain overgrowth
P Vabres,1 VE Parker,2 J St-Onge,3 Y Duffourd,3 RG Knox,2 RK Semple,2 L Faivre3 and J Riviere3 1Dermatology, Centre Hospitalier
Universitaire, Dijon, France, 2The University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science,
Cambridge, United Kingdom and 3GAD Research Group, Université de Bourgogne Franche-Comté, Dijon, France
15.10-15.20
Post-zygotic mutations in GNA11 and GNAQ cause phakomatosis pigmentovascularis
A Thomas,1 Z Zeng,2 J Riviere,3 R O’Shaughnessy,1 L Al-Olabi,1 J St-Onge,3 P Vabres,3 E Patton2 and VA Kinsler1 1UCL Institute of
Child Health, London, United Kingdom, 2MRC Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom and 3Dijon
University Hospital, Dijon, France
15.20-15.30
Multi-ethnic genome-wide association study of 21,000 cases and 95,000 controls identifies 11 novel risk loci for atopic dermatitis
L Paternoster,2 M Standl,3 H Baurecht,1 DM Evans4 and S Weidinger1 1Department of Dermatology, Venereology and Allergy,
University Hospital Schleswig-Holstein, Kiel, Germany, 2MRC Integrative Epidemiology Unit, University of Bristol, United Kingdom,
3
Institute of Epidemiology I, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg,
Germany and 4University of Queensland Diamantina Institute, Translational Research Institute, University of Queensland, Brisbane,
Australia
15.30-15.40
Molecular mechanism underlying interstitial lung disease, nephrotic syndrome and epidermolysis bullosa
Y He,1 E Yalcin,2 M Balasubramanian,3 R O’Reilly,3 L Bruckner-Tuderman1 and C Has1 1University, Freiburg, Germany, 2University,
Ankara, Turkey and 3NHS Foundation Trust, Sheffield, United Kingdom
15.40-15.50
Nanogel coupled cutaneous enzyme delivery as protein replacement therapy for autosomal recessive congenital ichthyosis
(ARCI)
R Plank,1 R Casper,2 K Obst,3 M Hermann,4 M Calderón,5 S Hedtrich,3 KM Eckl1 and H Hennies1 1Center for Dermatogenetics, Div.
of Human Genetics, Innsbruck, Austria, 2Cologne Center for Genomics, Univ. of Cologne, Germany, 3Institute of Pharmaceutical
Sciences, Freie Universität Berlin, Germany, 4Dept. of Anaestesiology, Innsbruck Medical University, Austria and 5Inst. for Chemistry
and Biochemistry, Freie Universität Berlin, Germany
15.50-16.00
Decrease of intra-epidermal innervation in sensitive skin
V Buhé,1 K Vié,2 C Guéré,2 A Natalizio,3 C Lhéritier,3 J Carré1 and L Misery1 1Laboratory of Neurosciences of Brest, University of
Western Brittany, Brest, France, 2Clarins Laboratories, Pontoise, France and 3Dermscan Laboratory, Villeurbanne, France
55
Concurrent 10: Epidermal Structure & Function
Time: 14.30-16.00
Room: Mees Room
Chairs: Johanna Brandner, Emmanuela Camera, Joost Schalkwijk
14.30-14.40
Cytokine mediated induction of mTOR signalling prevents proper differentiation of keratinocytes and contributes to the
pathogenesis of psoriasis
C Bürger,1 M Hofmann,1 V Lang,1 S Diehl,1 B Malisiewicz,1 K Fotiou,1 W Boehncke2 and R Kaufmann1 1Department of Dermatology,
Goethe University, Frankfurt, Germany and 2Service de Dermatologie, Hôpital Universitaire de Genève, Geneva, Switzerland
14.40-14.50
FLG mutations lead to an inflammatory phenotype in AD HEEs
S Blunder,1 V Moosbrugger-Martinz,1 R Rühl,2 A Geisler,1 C Krimmel,1 R Gruber,1 M Schmuth1 and S Dubrac1 1Dermatology, Medical
University of Innsbruck, Austria and 2Biochemistry and Molecular Biology, University of Debrecen, Hungary
14.50-15.00
Healthy and diseased iPS cell-derived melanocytes for 3D skin modelling
KM Eckl,1 D de Lima Cunha,1 T Saric,2 R Plank,1 C Ploner3 and H Hennies1 1Division of Human Genetics, Medical University of
Innsbruck, Austria, 2Inst. for Neurophysiology, Medical Center, University of Cologne, Austria and 3Univ.-Clinics for Plastic,
Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, Austria
15.00-15.10
Initiation of cornification is regulated by Ca2+ and pH in isolated mouse stratum granulosum cells
T Matsui,1 A Hirabayashi,2 S Mayuko,3 K Toyooka3 and M Amagai4 1Laboratory for Skin Homeostasis, RIKEN Center for Integrative
Medical Sciences, Yokohama, Japan, 2KOSÉ Endowed Program for Skin Care and Allergy Prevention, Keio University School of
Medicine, Tokyo, Japan, 3Mass Spectrometry and Microscopy Unit, RIKEN Center for Sustainable Resource Science, Yokohama,
Japan and 4Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
15.10-15.20
Rab11A GTPase is essential for lamellar body trafficking in the human epidermis
M Reynier,1 S Allart,2 E Gaspard,1 A Moga,3 D Goudounèche,4 G Serre,1 M Simon1 and C Leprince1 1UDEAR - UMR 5165 CNRS, 1056
INSERM, Université de Toulouse, France, 2U1056 Institut National de la Santé et de la Recherche Médicale, Toulouse, France,
3
Synelvia, Labège, France and 4Centre de Microscopie Electronique Appliquée à la Biologie (CMEAB), Faculté de Médecine Rangueil,
University of Toulouse, France
15.20-15.30
Wnt signaling drives epidermal keratinocyte differentiation in an adhesion-dependent manner
A Galichet, C Strauss, BS Sayar and EJ Müller Animal Pathology, University of Bern, Switzerland
15.30-15.40
Loss of keratinocyte type VII collagen induces pro-carcinogenic transcriptomic pathways
S Marsh,1 V Martins,1 M Caley,1 M Barnes,1 MJ Donaldson2 and E O’Toole1 1Centre for Cell Biology and Cutaneous Research, Barts
and The London School of Medicine and Dentistry, Queen Mary, University of London, United Kingdom and 2Stiefel, a GSK company,
Uxbridge, United Kingdom
15.40-15.50
Active RIPK4 levels are kept low in keratinocytes by continuous proteasome-dependent degradation
G Tanghe, C Urwyler, K Leurs, P De Groote, B Gilbert, P Vandenabeele and W Declercq VIB-Ghent University, Ghent, Belgium
15.50-16.00
Epidermal hyperinnervation is mediated by VEGF-A in an imiquimod-induced itchy psoriasiform model
L Wong, A Otsuka, Y Yamamoto and K Kabashima Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan
56
General
Information
57
ESDR 2015 MEETING VENUE AND TRAVEL INFORMATION
ESDR 2015 Meeting Venue
The 45th Annual ESDR Meeting will be held at the Postillion Convention Centre-WTC, Rotterdam. Located within walking
distance of the main train station, this modern and comfortable building has state-of-the-art meeting facilities.
Postillion Convention Centre-WTC, Rotterdam
Beursplein 37, Rotterdam
3001 DB Rotterdam
The Netherlands
Tel: +31 10 405 4444
http://www.postillionhotels.com/en-us/postillion-hotel-wtc/
Travel Information
From Rotterdam Central Station
Metro: Take the subway and get off at station ‘Beurs’ (second station), exit Beursplein.
Tram: Take tramline 8, 21, 23, 24 or 25. Get off at the Coolsingel, stop ‘Beurs’, in front of ABN AMRO Bank.
Walking: You can walk in approximately 10 minutes to Postillion Convention Centre-WTC. Follow the signs Stadhuis or
Beurs
GENERAL INFORMATION
REGISTRATION DESK
SPEAKER PREVIEW ROOM
The Registration desk is located on the ground floor.
All speakers must take their presentations to the Speaker Preview Room
ahead of their talks. Presenters are advised that they cannot connect their
own computers in the meeting rooms.
Opening Hours
Wednesday 9 September
Thursday 10 September
Friday 11 September
Saturday 12 September
08.30-18.30
07.15-19.00
08.00-18.15
08.00-16.30
Opening Hours
Wednesday 9 September
Thursday 10 Septmber
Friday 11 September
08.00 to 18.00
07.30 to 18.30
08.00 to 18.00
08.00 to 14.30
EXHIBITION
The exhibition is open to all registered ESDR delegates who have indicated on the registration form that they are “PRESCRIBERS”.
Opening Hours
Thursday 10 September
Friday 11 September
10.00-17.00
10.00-17.00
10.00-14.00
EXHIBITOR
IPC
Celgene
Aeon Astron Europe/Biomimiq
Cytoo
Fibrotx LLC
RiverD international
CELLnTEC Advanced Cell Systems
58
Booth Number
1
6
7
9
10
11
12
PRACTICAL INFORMATION
Certificate of Attendance
Will be sent by email upon request by h.vandenhengel@erasmusmc.nl , after the meeting.
Credit Cards
All major credit cards are in general use in The Netherlands. At the registration desk you can only use Visa and Mastercard.
Duplication, Recording, Photos
Photography, audio-taping, video-recording, or any other form of duplication is strictly prohibited in the session rooms and poster areas.
Failure to comply with this rule could lead to your meeting credentials being removed.
Food & Beverage
Lunch is not served to delegates as part of the registration fee. A range of cafes and restaurants are within walking distance of the venue.
Insurance
Delegates are advised to take out their own comprehensive travel insurance as the organisers shall not be liable for personal accidents,
illness, losses or damage to private property.
Internet
Wifi at the venue is available free of charge.
Language
The official meeting language is English.
Meeting App
The 2015 ESDR Meeting app is available for phones and tablets running IOS or Android. Once downloaded the app does not require an
internet connection to function.
The meeting app contains all ESDR 2015 program information, general information and search functionality. You can also add events to
customise your meeting program.
Membership
If you wish to apply for membership of the ESDR, forms are available at the registration desk. For membership enquiries after the meeting,
please contact the ESDR: office@esdr.org
Name Badge
It is essential that you wear your name badge at all times while in the meeting venue and during the Social Events.
Restaurants
A number of restaurants are located near the meeting venue. For more information please visit the registration desk.
Smoking
All interior areas are non-smoking at the ESDR meeting venue. Smoking is permitted outside the main entrance. Please note that in The
Netherlands smoking is restricted in most public places, including restaurants.
Taxi
Rotterdam Taxi Centrale: +31 10 462 6464 or http://www.rtcnv.nl/
Taxi St Job: +31 10 425 7000 or http://st-job.nl/cms/index.html
Tipping
Service charges are always included.
Weather
Rotterdam has temperate oceanic climate. In early-mid September the weather is usually dry and pleasant with daytime temperatures
around 11°C – 21°C. However, rain may occur, so it is advisable to bring a light raincoat or umbrella.
Services for ESDR 2015 delegates
Registered delegates are entitled to the following services and material:
•
•
•
•
admission to all meeting sessions and to the welcome and closing ceremonies
abstract book, program book and meeting bag
coffee/tea/water
welcome reception at the Postillion Convention Centre-WTC on Thursday 10 September
59
POSTER INFORMATION
Installation and Removal
• Printed posters must be installed on Thursday 10 September (poster areas open at 09.00). If you have used ESDR's
poster printing service, please collect your poster from the registration desk.
• Please remove your poster by 17.00 on Saturday 12 September. Posters remaining after this time will be destroyed.
Poster Sessions
Two Poster Sessions are scheduled in addition to the general poster viewing session on Thursday 10 September
• POSTER SESSION I (ODD NUMBERS) Friday 11 September 2015, 11.30-13.00
All poster presenters of odd-numbered posters to stand in front of posters, except those joining poster walks (see
below). Coffee will be available during this session.
• POSTER SESSION 2 (EVEN NUMBERS) Saturday 12 September 2015, 11.30-13.00
All poster presenters of even-numbered posters to stand in front of posters, except those joining poster walks (see
below). Coffee will be available during this session.
ELECTRONIC POSTER AREA
All 2015 ESDR posters will be available for viewing throughout the meeting at the Electronic Poster Area. This
area contains 20 computers and is only available for poster viewing (no Internet connection). The Electronic Poster
technology enables fast browsing/search and a facility to contact the author. A technician will be available to assist with
any questions/problems.
If you did not send your electronic poster prior to the 2015 ESDR meeting by email you may hand it to a technician at
the Electronic Poster Area.
The 2015 ESDR Electronic Poster area is supported by
POSTER PRIZES
Several poster prizes will be awarded at the 2015 ESDR Meeting. The awards will be made at the closing ceremony on
Saturday 12 September 2015.
POSTER WALKS
Poster walks will take place during poster viewing sessions from 12.00-13.00 on Friday 11 September and Saturday 12
September. The walks are guided thematic tours of selected posters accompanied by a senior investigator. Each poster
presenter will be asked to briefly describe their work and a short group discussion will be held. If your poster has been
selected for a Poster Walk, please join the appropriate group in the main Poster Area, near to Poster #001.
The 2015 ESDR Poster Walks are supported by
Poster Walker
Day
Topic
Poster Numbers
Lionel Larue
Alexander Navarini
Ryan O’Shaughnessy
Thierry Passeron
Friday
Friday
Friday
Friday
Cancer
Inflammation & Immunity
Epidermal Structure
Photobiology
116, 119, 120, 123, 127, 130, 147, 148
016, 023, 053, 054, 062, 357, 415, 443
254, 262, 265, 278, 285, 286, 299, 311
467, 473, 477, 478, 480, 484, 485, 493
Cristina Has
Jo Lambert
Errol Prens
Kerstin Steinbrink
Saturday
Saturday
Saturday
Saturday
Genetic Disorders
Clinical Research
Psoriasis
Immunology: Diseases
tba
190, 191, 193, 198, 199, 200, 204, 206
026, 034, 064, 067, 073, 082, 202, 312
025, 035, 061, 083, 430, 431, 440, 453
TRAVEL GRANTS
2015 ESDR travel grants were supported by
60
CURRENT ESDR EXECUTIVE COMMITTEE AND BOARD
Executive Committee
PRESIDENT
M. Picardo, Rome
SECRETARY-TREASURER
J. Barker, London
PRESIDENT-ELECT
J. Barker, London
PAST-PRESIDENT
N. Reynolds, Newcastle
SECRETARY-TREASURER-ELECT
M. Gilliet, Lausanne
Board Members
S. Aznar-Benitah, Barcelona
Z. Bata-Csörgõ, Szeged
C. Griffiths, Manchester
M. Hertl, Marburg
A. Hovnanian, Paris
D. Kelsell, London
L. Larue, Paris
A. Lauerma, Helsinki
M. Schmuth, Innsbruck
K. Steinbrink, Mainz
M. Vermeer, Leiden
T. Werfel, Hannover
ESDR COMMITTEES
Membership, Board, Honours
Jonathan Barker (Chair)
Lionel Larue
Antti Lauerma
Kerstin Steinbrink
Thomas Florestan (ESDR Office)
Caroline Blondel Baldassarre (ESDR
Office)
Poster Committee
Zsuzsanna Bata-Csörgõ (Chair)
Alain Hovnanian
Lionel Larue
Eastern Europe Committee
Zsuzsanna Bata-Csörgõ (Chair)
Matthias Schmuth
Norbert Wikonkál
Anna Zalewska
Pharma Committee
Jonathan Barker
Chris Griffiths
Michael Hertl
Thomas Werfel
Caroline Blondel Baldassarre (ESDR
Office)
Education Committee
Michael Hertl (Chair)
David Kelsell
Lionel Larue
Antti Lauerma
Nick Reynolds
Matthias Schmuth
Kerstin Steinbrink
Thomas Werfel
Journal of Investigative Dermatology
Michel Gilliet (Chair)
Alain Hovnanian
John McGrath
Nick Reynolds
Thomas Werfel
Media
Salvador Aznar-Benitah (Chair)
David Kelsell
Antti Lauerma
Maarten Vermeer
Thomas Werfel
2015 Program Committee
David Kelsell (Vice-Chair)
Jonathan Barker
Michel Gilliet
Mauro Picardo
Matthias Schmuth
Maarten Vermeer
Thomas Werfel
Finance and Office Committee
Jonathan Barker (Chair)
Matthias Schmuth
PAST OFFICERS OF THE ESDR BOARD
Year 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 President F. Serri O. Braun-Falco S. Shuster H. Rorsman R. Cormane K. Wolff E. Jung E. Christophers R. Marks H. Schaefer E. Frenk M. Greaves G. Plewig W. van Vloten A. Giannetti J.H. Saurat P. Fritsch W.J. Cunliffe B. Vermeer J. Ring G.L. Vejlsgaard D.M. MacDonald G. Stingl P.S. Friedmann T. Krieg Secretary M. Prunieras M. Prunieras M. Prunieras M. Prunieras C. Lapière C. Lapière C. Lapière M. Greaves M. Greaves M. Greaves M. Greaves H. Hönigsmann H. Hönigsmann H. Hönigsmann W.J. Cunliffe W.J. Cunliffe W.J. Cunliffe G.L. Vejlsgaard G.L. Vejlsgaard G.L. Vejlsgaard P.S. Friedmann P.S. Friedmann P.S. Friedmann W. Sterry W. Sterry Year President Secretary-Treasurer
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
W. Sterry K. Thestrup-Pedersen R. Camp P. van de Kerkhof I. Leigh G. Zambruno L. Bruckner-Tuderman J. Rees M. Röcken L. French
T. Schwarz
C. Pincelli
J. McGrath
R. Dummer
E. Healy
V. Piguet
T. Biedermann
A. Enk
N. Reynolds
P. van de Kerkhof
P. van de Kerkhof
P. van de Kerkhof
L. Bruckner-Tuderman
L. French
L. French
L. French
M. Röcken
M. Röcken
M. Röcken
V. Piguet
V. Piguet
V. Piguet
A. Enk
A. Enk
J. Barker
J. Barker
Treasurer
R. Cormane
R. Cormane
R. Cormane
R. Cormane
E. Christophers
E. Christophers
E. Christophers
T. van Joost
W. van Vloten
W. van Vloten
W. van Vloten
W. van Vloten
W. van Vloten
B. Vermeer
B. Vermeer
B. Vermeer
B. Vermeer
R. Willemze
R. Willemze
R. Willemze
R. Willemze
R. Willemze
R. Willemze
P. van de Kerkhof
P. van de Kerkhof
61
ESDR PATRON MEMBERS
The ESDR acknowledges the ongoing support from its Patron Members. Patron memberships help support ESDR members
from Eastern Europe, the development of the JID and annual meeting-related projects.
Martine Bagot
Jonathan Barker
Zsuzsanna Bata-Csorgo
David R Bickers
Leena Bruckner-Tuderman
Alexander Enk
Lars E French
Peter S Friedmann
Michel Gilliet
Christopher E.M. Griffiths
Russell P. Hall
Eugene Healy
Michael Hertl
Alain Hovnanian
Roland Kaufmann
David Kelsell
Birgit Lane
Antti Lauerma
Lotus Mallbris
Ludovic Martin
Cornelia Mauch
Dedee F Murrell
Michael P Philpott
Mauro M. Picardo
Vincent Piguet
Gerd Plewig
Nicholas J Reynolds
Lesley E Rhodes
Johannes Ring
Martin Roecken
Joerg Schaller
Matthias Schmuth
Thomas Schwarz
Guy Bruno Serre
Mona Stahle
Georg Stingl
Kristian Thestrup-Pedersen
Erwin Tschachler
Jouni Uitto
Peter CM van de Kerkhof
Maarten H Vermeer
John J Voorhees
ESDR ABSTRACT REVIEWERS
The ESDR acknowledges the great contributions of the following 2015 ESDR abstract reviewers who donated their time and
efforts to peer-review this year‘s submissions:
Hervé Bachelez
Jonathan Barker
Andrea Cavani
Antonio Costanzo
Giovanni Di Zenzo
Beate Eckes
Judith Fischer
Carsten Flohr
Olivier Gaide
Marjan Garmyn
Kamran Ghoreschi
Michel Gilliet
ChristopherGriffiths
Muzz Haniffa
Matthew Hardman
Cristina Has
Bernard Homey
Alain Hovnanian
Delphine Javelaud
Kim Jensen
Marcel Jonkman
Veli-Matti Kähäri
York Kamenisch
David Kelsell
Maranke Koster
Lionel Larue
Antti Lauerma
FUTURE ESDR MEETINGS
2016
46th Annual ESDR Meeting
Munich, Germany
7-10 September 2016
2017
47th Annual ESDR Meeting
Salzburg, Austria
27-30 September 2017
2018
International Investigative Dermatology
Orlando, Florida
16-19 May 2018
62
Thierry Magnaldo
Karsten Mahnke
John McGrath
Catherin Niemann
Carien Niessen
Tamar Nijsten
Edel O’Toole
Thierry Passeron
Ralf Paus
Sirkku Peltonen
Michael Philpott
Ehrhardt Proksch
Nick Reynolds
Matthias Schmuth
Thomas Schwarz
Michel Simon
Catherine Smith
Eli Sprecher
Kerstin Steinbrink
Des Tobin
Maarten Vermeer
Thomas Werfel
Norbert Wikonkal
Antony Young
Patrick Zeeuwen
Christina Zielinski
ESDR HONORARY MEMBERS AND AWARDS
Year
ESDR Awards
ESDR Honorary Members
2015
Masayuki Amagai (Japan), Leena Bruckner-Tuderman (Germany)
2014
Robin Eady (UK), Wolfram Sterry (Germany)
2013
Ronald Marks (UK), Hiroshi Shimizu (Japan), Peter van de Kerkhof (Netherlands)
2012
Johannes Ring (Germany)
2011
Paul Bergstresser (USA), Koji Hashimoto (Japan), Anders Vahlquist (Sweden)
2010
Alberto Giannetti (Italy), Shinji Shimada (Japan)
2009
Ervin Epstein (USA), Peter Friedmann (UK)
2008
Kristian Thestrup-Pedersen (Denmark), William Cunliffe (UK)
2007
Thomas Krieg (Germany), John Stanley (USA)
2006
Rona MacKie (UK), Rein Willemze (Netherlands)
2003
Georg Stingl (Austria), Jouni Uitto (USA)
2000
J.P. Ortonne (France)
J-H. Saurat (Switzerland)
1999
M. Greaves (UK)
E. Macher (Germany)
1998
1997
L. Juhlin (Sweden)
1996
O. Braun-Falco (Germany)
J. Thivolet (France)
A. Giannetti (Italy)
D. McDonald (UK)
T. Nishikawa (Japan), J. Voorhees (USA)
Previously Awarded
F. Serri (Italy), M. Prunieras (France)
O. Braun-Falco (Germany), R. Cormane (Netherlands)
R. Brun (Switzerland), A. Kint (Belgium)
Ch. Lapière (Belgium), K. Mustakallio (Finland)
H. Rorsman (Sweden), S. Shuster (UK)
K. Wolff (Austria)
S. Jablonska (Poland), H. Ueki (Japan)
W. van Vloten (Netherlands)
E. Christophers (Germany)
S. Katz (USA)
S. Imamura (Japan)
63
LOOK INSIDE THE CELL FOR A NEW PERSPECTIVE
DISCOVER THE ROLE OF
PDE4 IN PSORIASIS AND
PSORIATIC ARTHRITIS
PDE4 promotes the dysregulation of pro- and anti-inflammatory mediators thought to
occur in inflammatory disease1,2 and is present in key inflammatory cells implicated in
psoriasis and psoriatic arthritis.2-4
Visit discoverPDE4.com
PDE4=phosphodiesterase 4; AMP=adenosine monophosphate; cAMP=cyclic AMP.
References: 1. Houslay MD, Schafer P, Zhang KYJ. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503-1519.
2. Press NJ, Banner KH. PDE4 inhibitors – a review of the current field. In: Lawton G, Witty DR, eds. Progress in Medicinal Chemistry. Amsterdam,
The Netherlands: Elsevier; 2009:37-74. 3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866-873.
4. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis. 2005;64(suppl 2):ii26-ii29.
© 2014 Celgene Corporation Date of Preparation June 2014 UK-I&I140007b
64
PDE4
cAMP
AMP
65

a PDF version of the Final Program Book here

Transcription

Similar documents

Pharmacy Guild Portal Instructions

Alexander Palmestål Portfolio 2016 alexanderpalmestal.com

Psoriasiform Dermatitis

LAMP POST OCTOBER, 2013

Psoriasiform reaction pattern

Welcome to the Dermatology Institute For Skin Cancer + Cosmetic

Welcome to the Dermatology Institute For Skin Cancer + Cosmetic

Teknik Presentasi Hasil Penelitian Poster

STA - Schalmont Teachers Association

Scalp Psoriasis - The Psoriasis and Psoriatic Arthritis Alliance

- Wiley Online Library